Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

A.R. Falsey, M.E. Sobieszczyk, I. Hirsch, S. Sproule, M.L. Robb, L. Corey, K.M. Neuzil, W. Hahn, J. Hunt, M.J. Mulligan, C. McEvoy, E. Dejesus, M. Hassman, S.J. Little, B.A. Pahud, A. Durbin, P. Pickrell, E.S. Daar, L. Bush, J. Solis, Q.O. Carr, T. Oyedele, S. Buchbinder, J. Cowden, S.L. Vargas, A.G. Benavides, R. Call, M.C. Keefer, B.D. Kirkpatrick, J. Pullman, T. Tong, M.B. Isaacs, D. Benkeser, H.E. Janes, M.C. Nason, J.A. Green, E.J. Kelly, J. Maaske, N. Mueller, K. Shoemaker, T. Takas, R.P. Marshall, M.N. Pangalos, T. Villafana, and A. Gonzalez-Lopez, for the AstraZeneca AZD1222 Clinical Study Group*

ABSTRACT

BACKGROUND

The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known.

METHODS

In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru.

RESULTS

A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose.

CONCLUSIONS

AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.)

The New England Journal of Medicine
Downloaded from nejm.org by BETH KIRKPATRICK on September 29, 2021. For personal use only. No other uses without permission. Copyright © 2021 Massachusetts Medical Society. All rights reserved.
Previous clinical trials have shown the safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in preventing coronavirus disease 2019 (Covid-19) in diverse epidemiologic settings, including Brazil and the United Kingdom.1-3 Accordingly, AZD1222 is being distributed for vaccination in more than 100 countries across six continents and has been administered to hundreds of millions of persons.4

We report results from the primary analysis of a pivotal phase 3, double-blind, placebo-controlled trial that assessed the safety, efficacy, and immunogenicity of two doses of AZD1222 administered 4 weeks apart for the prevention of symptomatic Covid-19 confirmed by reverse-transcriptase–polymerase-chain-reaction (RT-PCR) testing. This trial of AZD1222 was designed to include diverse groups at high risk for exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and populations at increased risk for Covid-19 complications.

Methods

Trial Oversight

This is an ongoing phase 3, double-blind, placebo-controlled trial conducted at 88 sites in the United States, Chile, and Peru in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines. The trial protocol (available with the full text of this article at NEJM.org) and six amendments were approved by the ethics committee or institutional review board at each center, and all participants provided written informed consent before enrollment. Safety is reviewed on a continual basis. Data were gathered by the trial site investigators in collaboration with a contract research organization (IQVIA) and AstraZeneca and analyzed by IQVIA and AstraZeneca. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. All authors contributed to the writing and editing of the manuscript and reviewed and approved the manuscript for submission. Medical writing assistance was funded by AstraZeneca. Agreements requiring authors to maintain data confidentiality were in place between the sponsor and the authors.

Trial Design and Population

The trial was designed by AstraZeneca in collaboration with the Department of Health and Human Services and the National Institutes of Health and the trial cochairs.5,6 The objectives of the trial were to assess the safety, efficacy, and immunogenicity of AZD1222 as compared with placebo for the prevention of symptomatic Covid-19 in participants 18 years of age or older whose conditions were medically stable and who were at increased risk for SARS-CoV-2 infection, including high risk for symptomatic and severe Covid-19. Key inclusion and exclusion criteria along with definitions and descriptions of testing protocols are provided in the Supplementary Appendix, available at NEJM.org.

Participants received two intramuscular injections of either AZD1222 (5×10^{10} viral particles) or saline placebo administered 4 weeks apart on days 1 and 29 (−3 to +7 days). Random assignment was in a 2:1 ratio to increase the number of participants who received AZD1222. Randomization was stratified according to age (≥218 to 64 years and ≥65 years), with a target of 25% or more of the participants 65 years of age or older. The safety analysis population was defined as all participants who received at least one dose of AZD1222 or placebo, with participants grouped according to the actual vaccine or placebo received. The fully vaccinated analysis population included all participants who were SARS-CoV-2 seronegative at baseline, who received two doses of vaccine or placebo, and who remained in the trial for 15 days or more after their second dose and did not have a previous confirmed SARS-CoV-2 RT-PCR–positive infection.

Participants were reminded weekly to monitor for Covid-19 symptoms. Participants who had one or more qualifying symptoms of Covid-19 underwent illness evaluations and SARS-CoV-2 testing. All trial participants were scheduled to have serum collected for SARS-CoV-2 antibody testing to assess the efficacy of the vaccine, regardless of the presence or severity of symptoms. All participants will remain in the study for 2 years (730 days) after receipt of the first dose of AZD1222 or placebo for safety follow-up and assessment of durability of immune response.

A substudy to further assess reactogenicity and immunogenicity of AZD1222 included the
first participants who underwent randomization in each age group in the United States (1500 participants 18 to 55 years of age, 750 participants 56 to 69 years of age, and 750 participants 70 years of age or older). These participants completed symptom diaries after vaccination and had additional blood samples obtained on days 15 and 43.

SAFETY AND REACTOGENICITY
Unsolicited adverse events were recorded for all participants for 28 days after each dose of AZD1222 or placebo, and serious adverse events will be recorded from the time of signed informed consent through day 730. Medically attended adverse events and adverse events of special interest will be recorded from day 1 after the first dose through day 730. Reactogenicity was evaluated in the substudy group to investigate the incidence of solicited local and systemic adverse events for 7 days after each dose of AZD1222 or placebo.

EFFICACY
The primary efficacy end point was the first occurrence of SARS-CoV-2 symptomatic illness, confirmed by positive results on RT-PCR testing, with onset 15 days or more after the second dose of vaccine or placebo among participants who were seronegative for Covid-19 at baseline (descriptions of end points and analyses are provided in the Supplementary Appendix). Estimated vaccine efficacy was analyzed according to demographic subgroups of interest.

Key secondary end points included the incidence of symptomatic illness (at 15 days or more after the second dose) regardless of evidence of previous SARS-CoV-2 infection at baseline, severe or critical symptomatic Covid-19, Covid-19–related emergency department visits, symptomatic Covid-19 as defined by Centers for Disease Control and Prevention (CDC) criteria, and SARS-CoV-2 infection regardless of symptoms or severity, measured as a post-treatment serologic response (negative at baseline and positive after baseline) for SARS-CoV-2 nucleocapsid antibodies. Estimated vaccine efficacy was analyzed for exploratory end points, including the incidence of Covid-19–related hospitalizations and intensive care unit (ICU) admissions.

HUMORAL IMMUNOGENICITY AND WHOLE-GENOME SEQUENCING
As prespecified, immunogenicity analyses, which included analysis of antibodies to spike proteins and nucleocapsid proteins and neutralizing antibodies, were performed on serum samples obtained from participants in the substudy group during the trial to assess antibody titers and responses to SARS-CoV-2 antigens. Saliva specimens were collected at clinical sites or provided by trial participants at illness visits. Specimens positive for SARS-CoV-2 on RT-PCR testing were available for next-generation sequencing.

STATISTICAL ANALYSIS
The required number of symptomatic Covid-19 events for the primary analysis was approximately 150 and was reached after independent determination that the interim analysis criteria had been met. The cutoff date for the primary analysis was March 5, 2021. Adjudication of 14 outstanding potential cases that occurred before the cutoff date was conducted in parallel with the initial primary analysis. Once all events that occurred before the data cutoff had been fully adjudicated, the data analysis was refreshed and reflects the final data presented here. Data from participants whose treatment assignment was unmasked or from participants who received a Covid-19 vaccine administered under an emergency use authorization (EUA) were censored at the date of unblinding to the group assignment or EUA vaccine administration, whichever was earlier. All other participant data were censored at the date of the last trial contact. All deaths that were adjudicated as related to Covid-19 were included as a primary efficacy end-point event. Deaths that were adjudicated as not related to Covid-19 were treated as intercurrent events and therefore censored at the date of death.

The primary efficacy end point was a binary response, whereby a participant’s status was classified as symptomatic Covid-19 or not, before the end of the follow-up period. We used a Poisson regression model with robust variance adjusted for follow-up time as the primary efficacy analysis model to estimate the relative risk of the incidence of symptomatic infection in the AZD1222 group as compared with the placebo group. We calculated vaccine efficacy as 1 minus...
the relative risk, with the result expressed as a percentage. The success criterion for the primary efficacy end point was statistical significance with an observed vaccine efficacy point estimate of at least 50%. A sensitivity analysis was performed with the use of a multiple imputation approach to evaluate the robustness of the analysis of the primary end point to missing data after censoring. Additional details on the statistical analyses are provided in the Supplementary Appendix.

**RESULTS**

**TRIAL POPULATION**

Between August 28, 2020, and January 15, 2021, a total of 34,117 unique participants were screened, 32,451 of whom met eligibility criteria and underwent randomization to receive the AZD1222 vaccine (21,635 participants) or placebo (10,816 participants) (Fig. 1). The majority of participants were men (55.6%) and had at least one coexisting condition (59.2%); the mean (±SD) age was 50.2±15.9 years (Table 1). Overall, 79.0% of the participants were White, 8.3% were Black, 4.4% were Asian, 4.0% were American Indian or Alaska Native, 2.4% were of multiple races or ethnic groups, 0.3% were Native Hawaiian or other Pacific Islander, and the remainder were of unknown or unreported race or ethnic group. Across both groups, 22.3% of participants were Hispanic or Latinx. Baseline demographic and clinical characteristics were balanced between the trial groups in both the safety analysis population (Table 1) and the fully vaccinated analysis population (Table S1 in the Supplementary Appendix). A total of 347 participants (1.6%) in the AZD1222 group and 169 (1.6%) in the placebo group were living with well-controlled human immunodeficiency virus infection.

**SAFETY**

The incidence of adverse events is shown in Table S2. A total of 11,972 participants (37.0%) — 8771 (40.6%) in the AZD1222 group and 3201 (29.7%) in the placebo group — reported 23,538 adverse events. The most common adverse events, occurring in at least 5% of participants within 28 days after any dose in either group, were general pain (8.2% in the AZD1222 group and 2.3% in the placebo group), headache (6.2% and 4.6%, respectively), injection-site pain (6.8% and 2.0%), and fatigue (5.1% and 3.5%).

A similar percentage of participants in each group had a serious adverse event within 28 days after any dose: 119 serious adverse events occurred among 101 participants (0.5%) in the AZD1222 group and 59 events among 53 participants (0.5%) in the placebo group. During the entire trial period, a total of 7 adverse events leading to death occurred in 7 participants in the AZD1222 group, and 9 adverse events leading to 7 deaths occurred in the placebo group. These deaths are described in Table S2. No deaths were considered by investigators to be related to the vaccine or placebo. No deaths related to Covid-19 occurred in the AZD1222 group, and two deaths related to Covid-19 occurred in the placebo group.

Medically attended adverse events and adverse events of special interest within 28 days after a dose also occurred in similar proportions in the two groups (Table S2). The incidences of individual adverse events related to the vaccine or placebo during the entire trial period are shown in Tables S3 through S5. The incidence of potential immune-mediated conditions was similar in
the two groups (1.8% in the AZD1222 group and 3.4% in the placebo group), as were the incidences of adverse events of special interest: neurologic (0.5% in the AZD1222 group and 0.4% in the placebo group), vascular (0.1% in the AZD1222 group and <0.1% in the placebo group), and hematologic (<0.1% in both groups). Specifically, the incidences of deep-vein thrombosis (<0.1% in both groups), pulmonary embolism (<0.1% in both groups), thrombocytopenia (<0.1% in the AZD1222 group and none in the placebo group), and immune thrombocytopenia (none in the AZD1222 group and <0.1% in the placebo group) were low and similar in the groups. There were no cases in either group of thrombosis with thrombocytopenia, cerebral...
Table 1. Demographic and Clinical Characteristics of the Safety Population at Baseline.*

| Characteristic                                | AZD1222 (N = 21,587) | Placebo (N = 10,792) | Total (N = 32,379) |
|-----------------------------------------------|-----------------------|----------------------|--------------------|
| Follow-up time from second dose — days†      |                       |                      |                    |
| Mean                                          | 64.8±21.4             | 64.9±21.7            | NA                 |
| Median                                        | 61.0                  | 61.0                 | NA                 |
| Range                                         | 1–129                 | 1–129                | NA                 |
| Age — yr:‡                                    |                       |                      |                    |
| Mean                                          | 50.2±15.9             | 50.2±15.9            | 50.2±15.9          |
| Median                                        | 51.0                  | 51.0                 | 51.0               |
| Range                                         | 18–100                | 18–92                | 18–100             |
| Age group — no. (%)                           |                       |                      |                    |
| ≥18 to 64 yr                                  | 16,760 (77.6)         | 8381 (77.7)          | 25,141 (77.6)      |
| ≥65 yr                                        | 4827 (22.4)           | 2411 (22.3)          | 7238 (22.4)        |
| Sex — no. (%)                                 |                       |                      |                    |
| Male                                          | 12,012 (55.6)         | 6003 (55.6)          | 18,015 (55.6)      |
| Female                                        | 9575 (44.4)           | 4789 (44.4)          | 14,364 (44.4)      |
| Hispanic or Latinx ethnic group — no. (%)§    |                       |                      |                    |
| No                                            | 16,470 (76.3)         | 8200 (76.0)          | 24,670 (76.2)      |
| Yes                                           | 4771 (22.1)           | 2452 (22.7)          | 7223 (22.3)        |
| Not reported                                  | 296 (1.4)             | 125 (1.2)            | 421 (1.3)          |
| Unknown                                       | 50 (0.2)              | 15 (0.1)             | 65 (0.2)           |
| Race or ethnic group — no. (%)§               |                       |                      |                    |
| White                                         | 17,061 (79.0)         | 8522 (79.0)          | 25,583 (79.0)      |
| Black                                         | 1794 (8.3)            | 892 (8.3)            | 2686 (8.3)         |
| Asian                                         | 947 (4.4)             | 481 (4.5)            | 1428 (4.4)         |
| American Indian or Alaska Native             | 851 (3.9)             | 429 (4.0)            | 1280 (4.0)         |
| Multiple                                      | 510 (2.4)             | 256 (2.4)            | 766 (2.4)          |
| Native Hawaiian or other Pacific Islander     | 61 (0.3)              | 21 (0.2)             | 82 (0.3)           |
| Not reported                                  | 262 (1.2)             | 137 (1.3)            | 399 (1.2)          |
| Unknown                                       | 101 (0.5)             | 54 (0.5)             | 155 (0.5)          |
| Country — no. (%)                             |                       |                      |                    |
| United States                                 | 19,145 (88.7)         | 9572 (88.7)          | 28,717 (88.7)      |
| Chile                                         | 1470 (6.8)            | 729 (6.8)            | 2199 (6.8)         |
| Peru                                          | 972 (4.5)             | 491 (4.5)            | 1463 (4.5)         |
| SARS-CoV-2 serostatus — no. (%)¶             |                       |                      |                    |
| Negative                                      | 20,593 (95.4)         | 10,296 (95.4)        | 30,889 (95.4)      |
| Positive                                      | 623 (2.9)             | 292 (2.7)            | 915 (2.8)          |
| Indeterminate                                 | 0                     | 0                    | 0                  |
| Missing data                                  | 117 (0.5)             | 60 (0.6)             | 177 (0.5)          |
| Not performed                                 | 254 (1.2)             | 144 (1.3)            | 398 (1.2)          |
| Coexisting conditions — no./total no. (%)‖     |                       |                      |                    |
| Any coexisting condition at baseline          | 12,753/21,585 (59.1)  | 6426/10,790 (59.6)   | 19,179/32,375 (59.2) |
| History of obesity**                          | 5808/21,585 (26.9)    | 3011/10,790 (27.9)   | 8819/32,375 (27.2) |
venous sinus thrombosis, or venous thrombosis in unusual locations.

**Reactogenicity**

In the substudy population, more participants in the AZD1222 group than in the placebo group had local solicited adverse events (74.1% in the AZD1222 group vs. 24.4% in the placebo group) and systemic solicited adverse events (71.6% vs. 53.0%) (Fig. 2). The majority of solicited adverse events (92.6%) across both groups were mild or moderate in intensity. Events occurred less frequently after the second dose than after the first dose in both age groups, a difference that was more marked in participants 18 to 64 years of age. The majority of local and systemic solicited adverse events resolved within 1 to 2 days after onset.

**Efficacy**

Once adjudication of all events that occurred before the data cutoff was complete, 203 symptomatic Covid-19 events met the case definition of the primary end point and were included in the updated primary analysis for the fully vaccinated analysis population (17,662 participants...
in the AZD1222 group and 8550 in the placebo group) (Fig. 1). The efficacy analyses presented here are based on the updated primary analysis of the group whose data were censored as of the cutoff date. In the full analysis population, the median follow-up duration from the second dose to the data cutoff date, regardless of unblinding of group assignments, was 61.0 days (range, 1 to 129) in both groups (Table 1). Overall, 73 events (0.4%) occurred in the AZD1222 group and 130 (1.5%) occurred in the placebo group (Fig. 3). For the primary efficacy end point, the success criterion was met in the fully vaccinated analysis population on the basis of an overall vaccine efficacy estimate of 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001).

Results regarding the cumulative incidence of the first SARS-CoV-2 RT-PCR–positive symptomatic illness after the second dose of AZD1222 (Fig. 4) showed that the effect of AZD1222 began soon after the second dose. Vaccine efficacy was consistent in the analyses in which follow-up data were not censored at unblinding of the treatment assignment or EUA vaccination (74.3%; 95% CI, 66.0 to 80.6) and also when multiple imputation was used (73.3%; 95% CI, 64.6 to 79.9).

On September 9, 2020, the trial was placed on clinical hold owing to an event of transverse myelitis reported in a different AZD1222 clinical study. After a review of the event and all available safety data, the Food and Drug Administration lifted the clinical hold on October 23, 2020, and the trial resumed on October 28, 2020. A total of 775 participants (2.4%) in the safety analysis population were affected by the clinical hold and received their second dose outside the planned 28-day window. Vaccine efficacy in this subgroup of participants who received their second dose at an extended dosing interval was consistent with that in the overall group (78.1%; 95% CI, 49.2 to 90.6).

Vaccine efficacy estimates according to subgroup are shown in Figure 3, although small case numbers hindered confidence in some subgroup estimates, such as those for ICU admissions and those based on data from participants in Chile and Peru. Estimated vaccine efficacy was high against symptomatic illness in participants 18 to 64 years of age (72.8%; 95% CI, 63.4 to 79.9) and those 65 years of age or older (83.5%; 95% CI, 54.2 to 94.1) and was consistent across participants of different races and ethnic groups, status with respect to coexisting conditions, baseline SARS-CoV-2 serostatus, and sex. In Chile, 4 cases of symptomatic illness were noted among 1360 participants in the AZD1222 group as compared with 2 cases among 672 participants in the placebo group. In Peru, 11 cases among 867 participants in the AZD1222 group and 9 cases among 435 participants in the placebo group were observed. Estimated vaccine efficacy against symptomatic Covid-19 regardless of evidence of previous SARS-CoV-2 infection (a secondary end point) was 73.7% (95% CI, 65.1 to 80.1; P<0.001).

The vaccine was significantly effective against all other key secondary efficacy end points (Fig. 3). In the fully vaccinated analysis population, no cases of severe or critical symptomatic Covid-19 were observed among the 17,662 participants. Estimated vaccine efficacy of AZD1222 for the prevention of Covid-19 (as defined by CDC criteria) was high (69.7%; 95% CI, 60.7 to 76.6; P<0.001), as was efficacy against emergency department visits attributed to Covid-19 (94.8%; 95% CI, 59.0 to 99.3; P=0.005),
with 1 (<0.1%) emergency department visit in the AZD1222 group and 9 (0.1%) in the placebo group. Estimated vaccine efficacy against Covid-19–related hospitalizations (an exploratory end point) was 94.2% (95% CI, 53.3 to 99.3) (Fig. 3). One participant in the AZD1222 group who had a Covid-19–related emergency department visit had an allergic reaction to a monoclonal antibody treatment and was hospitalized. This hospitalization did not meet the criteria for severe or critical Covid-19.

The estimated vaccine efficacy for incidences of first SARS-CoV-2 RT-PCR–positive symptomatic illness occurring after the first dose of AZD1222 or placebo is described in Figure S1. AZD1222 was efficacious at preventing infection with SARS-CoV-2, as measured by nucleocapsid antibody seroconversion 15 days or more after the second dose; this included all participants who tested positive for SARS-CoV-2 nucleocapsid antibodies regardless of symptoms or severity (64.3%; 95% CI, 56.1 to 71.0; P<0.001). Additional details of the efficacy analyses are provided in the Supplementary Appendix.

**Humoral Immunogenicity**

Participants who received AZD1222 and were seronegative at baseline showed strong vaccine-induced serum IgG responses to the spike protein (Fig. S2). Levels of neutralizing antibodies were higher than baseline at all time points in the AZD1222 group, increasing further after a second dose, but remained low throughout the trial in the placebo group (Fig. S3).

**Whole-Genome Sequencing of SARS-CoV-2 Samples**

Among participants in the full analysis population (the 30,889 participants who were seronegative at baseline), whole-genome sequencing of saliva samples obtained from 176 participants in the AZD1222 group and 183 participants in the placebo group attending illness visits, regardless of qualifying symptoms, yielded four cases of variants of concern, including alpha and beta variants (one putative B.1.351 case was determined by clade). Of the variants of interest observed, epsilon was the most common (B.1.429 in 14 participants and B.1.427 in 3 participants) followed by iota (B.1.526 in 1 participant) (Table S6).

**Discussion**

AZD1222 is a safe and efficacious vaccine for the prevention of symptomatic Covid-19. In a diverse adult population of more than 32,000 participants, two doses of AZD1222 administered 4 weeks apart were 74% efficacious overall at preventing symptomatic illness 15 days or more after the second dose.

Success criteria for AZD1222 were met on the basis of the measured primary and secondary end points. When measured according to the CDC definition of Covid-19, which can include mild disease, AZD1222 had 70% efficacy. Furthermore, although event rates were low, participants who received AZD1222 had no cases of severe or critical symptomatic Covid-19 and had significantly fewer Covid-19–related emergency department visits, hospitalizations, and ICU admissions than participants who received placebo.

A key strength of this trial is that it showed the efficacy of AZD1222 across all age groups, including in adults 65 years of age or older. This finding is further supported by emerging real-world data from the United Kingdom that show high vaccine effectiveness for prevention of Covid-19, including severe disease and hospitalization in older adults, after the first AZD1222 dose.8-10

Because of small case numbers in Chile and Peru, we were unable to precisely estimate vaccine efficacy in those groups. This trial was not designed to assess vaccine efficacy according to enrollment country or in smaller subpopulations.

Although the level of SARS-CoV-2 neutralizing antibodies that correlates with protection is not yet known, the role of these antibodies as an important contributor to protective immunity is widely accepted.11 In our trial, both SARS-CoV-2 spike protein binding and neutralizing antibodies increased in all age groups after the first dose of AZD1222 and further increased from baseline when measured 28 days after the second dose, a finding consistent with results from previous trials.12

No new vaccine-related safety signals were identified, and solicited adverse events were mostly mild or moderate and were fewer in number after the second dose of AZD1222 than after the first. Results from this trial showed no evidence of increased overall risk of neurologic events,


**Figure 3. Estimated Vaccine Efficacy ≥15 Days after the Second Dose (Fully Vaccinated Analysis Population).**

Values shown for no. of events/total no. are the number of events that occurred among the participants within each group and do not account for censoring due to unblinding of group assignment or loss to follow-up. The primary efficacy end point is the first case of SARS-CoV-2 RT-PCR–positive symptomatic illness occurring 15 days or more after the second dose of AZD1222 or placebo among participants with negative serostatus at baseline. Vaccine efficacy is shown with 95% confidence intervals (CIs), except for vaccine efficacy values for the primary efficacy end point according to SARS-CoV-2 baseline serostatus, the secondary end point of severe or critical symptomatic Covid-19, and the exploratory end point of Covid-19–related intensive care unit (ICU) admissions, which are based on a one-sided 97.5% CI calculated with the exact Poisson model, owing to nonconvergence of the Poisson regression with robust variance. Race and ethnic group were reported by the participant. Other denotes participants who provided a race or ethnic group identification other than White, Black, or American Indian or Alaska Native. Key secondary end points were incidence of symptomatic illness (at 15 days or more after the second dose of AZD1222 or placebo) regardless of evidence of previous SARS-CoV-2 infection at baseline, severe or critical symptomatic Covid-19 (at 15 days or more after the second dose of AZD1222 or placebo), Covid-19-related emergency department visits, symptomatic Covid-19 as defined by Centers for Disease Control and Prevention (CDC) criteria, and first response (change from negative serostatus for SARS-CoV-2 nucleocapsid antibodies at baseline to positive serostatus after receiving AZD1222 or placebo). P values are reported for the primary and key secondary outcomes; analyses followed prespecified plan to adjust for multiple comparisons. I bars indicate confidence intervals; arrows indicate truncated values, with actual values shown in the accompanying column; the dashed vertical line represents the upper limit (i.e., 100% vaccine efficacy); and the solid vertical line represents the nominally statistically significant criterion of a lower confidence interval greater than 30% applicable to the primary end point and is shown for reference. NA denotes not available, and NE could not be estimated.
A comparison of data from different trials, including trials that evaluated the same vaccine, is challenging owing to numerous variables, such as difference in trial participants, symptomatic illness criteria, and circulating viruses. With dosing intervals ranging from 4 weeks, as reported here, to 12 weeks, as reported previously, AZD1222 has shown similar safety, side-effect profile, efficacy, and immunogenicity in adults in a pooled analysis of trials across different geographic locations, albeit with lower efficacy observed against mild-to-moderate disease in South Africa associated with the beta (B.1.351) variant.

A limitation of this trial is the early unblinding of group assignment for more than one third of participants, whose data were censored for most analyses. Unblinding occurred because other Covid-19 vaccines became authorized for use during the trial, allowing participants to make individual vaccination decisions. Other limitations include the small number of variants of concern owing to the timing of the trial within the pandemic and the short duration of follow-up, which also precludes evaluations of the duration of the efficacy and long-term safety of AZD1222. Analysis of the efficacy of the vaccine over time is ongoing. These data support AZD1222 as a safe and efficacious vaccine that prevents symptomatic and severe Covid-19 across diverse adult populations.

The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

Supported by AstraZeneca; funded in whole or in part under an agreement (W15QKN-20-9-1003) with the U.S. government; and supported by a contract (W15QKN-21-9-1003) with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, and awards (UM1 AI 148684, UM1 AI 148450, UM1 AI 148372, and UM1 AI 148574) from the Infectious Diseases Clinical Research Consortium through the National Institute of Allergy and Infectious Diseases, part of the NIH. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI 68614HVTN), the Statistics and Data Management Center (UM1 AI 68635), the HVTN Laboratory Center (UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI 68636), and the Infectious Diseases Clinical Research Consortium leadership group 5 (UM1 AI 148684-03). The U.S. government is authorized to reproduce and distribute reprints for governmental purposes notwithstanding any copyright notation thereon.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.
We thank the trial participants, caregivers, investigators, health care providers, and research staff who contributed to the trial; Raburn Mallory, the original clinical leader; Chris Brooks and Yee-Man Ching of AstraZeneca for coordinating the development, facilitating author discussions, and critically reviewing this manuscript; and Heather Shawcross, Kelly M. Hunter, Lucy Ree, Matilda Shackley, Jennifer Alexander, and Paul MacCallum, all of Fishawack Health, for medical writing and editing assistance with earlier drafts of the manuscript (funded by AstraZeneca), in accordance with Good Publication Practice guidelines (www.ismpp.org/gpp3). Additional acknowledgments are provided in the Supplementary Appendix.

APPENDIX

The authors’ full names and academic degrees are as follows: Ann R. Falsey, M.D., Magdalena E. Sobieszczyk, M.D., M.P.H., Ian Hirsch, Ph.D., Stephanie Sproule, M.Math., Merlin L. Robb, M.D., Lawrence Corey, M.D., Kathleen M. Neuzil, M.D., William Hahn, M.D., Julie Hunt, Ph.D., Mark J. Mulligan, M.D., Charlene McIvoy, M.D., M.P.H., Edwin Delosus, M.D., Michael Hassman, D.O., Susan J. Little, M.D., Barbara A. Pahud, M.D., M.P.H., Anna Durbin, M.D., Paul Pickrell, M.D., Eric S. Daar, M.D., Larry Bush, M.D., Joel Solis, M.D., Quito Osuna Carr, M.D., Temitope Oyede, M.D., Susan Buchbinder, M.D., Jessica Cowden, M.D., M.S.P.H., Sergio L Vargas, M.D., Alfredo Guerrero Benavides, M.D., Robert Call, M.D., Michael C. Keefer, M.D., Beth D. Kirkpatrick, M.D., John Pullman, M.D., Tina Tong, M.S., Margaret Brewinski Isaacs, M.D., M.P.H., David Benkeser, Ph.D., Holly E. Janes, Ph.D., Martha C. Nason, Ph.D., Justin A. Green, M.D., Ph.D., Elizabeth J. Kelly, Ph.D., Jill Maaske, M.D., Nancy Mueller, Ph.D., Kathyn Shoemaker, M.S., Therese Takas, B.S., Richard P. Marshall, M.D., Ph.D., Menelas N. Pangalos, F.Med.Sci, Ph.D., Tonya Villafana, Ph.D., M.P.H., and Antonio Gonzalez-Lopez, M.D., Ph.D., M.P.H.

The authors’ affiliations are as follows: the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), the University of Maryland School of Medicine (K.M.N.) and the Johns Hopkins Bloomberg School of Public Health (A.D.), Baltimore, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, Edgewood (J.C.), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (T. Tong, M.B.I., M.C.N.) — all in Maryland; the University of Washington (L.C., W.H.) and the Fred Hutchinson Cancer Research Center (L.C., W.H., J.H., H.E.J.), Seattle; HealthPartners Institute, St. Paul, MN (C.M.); Orlando Immunology Center, Orlando (E.D.), and JEM Headlands Research, Lake Worth Beach (L.B.) — both in Florida; Hassman Research Institute, Berlin, NJ (M.H.J.); the University of California San Diego, La Jolla (S.J.L.), the Lundquist Institute at Harbor–UCLA Medical Center, Torrance (E.S.D.), and the San Francisco Department of Public Health, San Francisco (S.B.) — all in California; Children’s Mercy Kansas City, Kansas City, MO (B.A.P.); Tekton Research, Austin (P.P.), and CenterX Studies, McAllen (S.S.) — both in Texas; Medpharmics, Albuquerque, NM (Q.O.C.); John H. Stroger, Jr. Hospital of Cook County, Chicago (T.O.); Instituto de Ciencias Exactas, Facultad de Medicina Universidad de Chile, Santiago, Chile (S.L.V.); Clínica Internacional Sede Lima, Lima, Peru (A.G.B.); Clinical Research Partners, Richmond, VA (R.C.); the University of Vermont Larner College of Medicine and UVM Medical Center, Burlington (B.D.K.); Mercury Street Medical Group, Butte, MT (J.P.); and the Rollins School of Public Health at Emory University, Atlanta (D.B.).

REFERENCES

1. Voysey M, Clemens SAC, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397:881-91.

2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.

3. Emery KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 2021;397:1351-62.

4. COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.ctracker.vaccines.org/vaccines/4/1).

5. Corey I, Mascola JR, Fauci AS, Collins F.S. A strategic approach to COVID-19 vaccine R&D. Science 2020;368:948-50.

6. Mehrotra DV, Janes HE, Fleming TR, et al. Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Ann Intern Med 2021;174:221-8.

7. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.

8. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test-negative case-control study. BMJ 2021;373:n1088.

9. Vasiliou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397:1646-57.

10. Hyams C, Marlows M, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis 2021 June 23 (Epub ahead of print).

11. Krammer F. Correlates of protection from SARS-CoV-2 infection. Lancet 2021; 397:1421-3.

12. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;398:1979-93.

13. Cines DB, Bussel JB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 384:2254-6.

14. Lee EJ, Cines DB, Germsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021;96:534-7.

15. Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous

N Engl J Med Downloaded from nejm.org by BETH KIRKPATRICK on September 29, 2021. For personal use only. No other uses without permission. Copyright © 2021 Massachusetts Medical Society. All rights reserved.
thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. May 11, 2021 (https://www.medrxiv.org/content/10.1101/2021.04.27.21256153v1). preprint.

16. European Medicines Agency. Vaxzevria: summary of product characteristics. Annex I. 2021 (https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf).

17. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: benefits and risks in context. April 23, 2021 (https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context).

18. Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021; 384: 1964-5.

19. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrie Pa, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384:2092-101.

20. Schultz NH, Servoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30.

21. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2202-11.

22. COVID-19 vaccines have prevented 10,400 deaths in older adults. Press release, April 8, 2021 (https://www.gov.uk/government/news/covid-19-vaccines-have-prevented-10-400-deaths-in-older-adults).

23. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78.

24. UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca. March 18, 2021 (https://www.gov.uk/government/news/uk-regulator-confirms-that-people-should-continue-to-receive-the-covid-19-vaccine-astrazeneca).

25. FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review. News release, April 23, 2021 (https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough).

26. Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines. Clin Infect Dis 2021 March 6 (Epub ahead of print).

27. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021;384:1885-98.

Copyright © 2021 Massachusetts Medical Society.
Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. DOI: 10.1056/NEJMoa2105290
Supplementary Appendix

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine

Ann R. Falsey, M.D.1, 2*, Magdalena E. Sobieszczyn, M.D., M.P.H.3*, Ian Hirsch, Ph.D.4, Stephanie Sproule, M.Math.5, Merlin L. Robb, M.D.6, Lawrence Corey, M.D.7,8, Kathleen M. Neuzil, M.D.9, William Hahn, M.D.7,8, Julie Hunt, Ph.D.8, Mark J. Mulligan, M.D., FIDSA10, Charlene McEvoy M.D., M.P.H. 11, Edwin DeJesus, M.D.12, Michael Hassman, D.O.13, Susan J. Little, M.D.14, Barbara A. Pahud, M.D., M.P.H.15, Anna Durbin, M.D.16, Paul Pickrell, M.D.17, Eric S. Daar, M.D.18, Larry Bush, M.D.19, Joel Solis, M.D.20, Quito Osuna Carr, M.D.21, Temitope Oyedele, M.D.22, Susan Buchbinder, M.D.23, Jessica Cowden, M.D., M.S.P.H.24, Sergio L. Vargas, M.D.25, Alfredo Guerreros Benavides, M.D.26, Robert Call, M.D.27, Michael C. Keefer, M.D.1, Beth D. Kirkpatrick, M.D.28, John Pullman, M.D.29, Tina Tong, M.S.30, Margaret Brewinski Isaacs, M.D., M.P.H.30, David Benkeser, Ph.D.31, Holly E. Janes, Ph.D.8, Martha C. Nason, Ph.D.30, Justin A. Green, M.D., Ph.D.32, Elizabeth J. Kelly, Ph.D.33, Jill Maaske, M.D.34, Nancy Mueller, Ph.D.35, Kathryn Shoemaker, M.S.5, Therese Takas, B.S.34, Richard P. Marshall, M.D., Ph.D.36, Menelas N. Pangalos, FMedSci, Ph.D.37, Tonya Villafana, Ph.D., M.P.H.34, Antonio Gonzalez-Lopez, M.D., Ph.D., M.P.H.34,†, on behalf of the AstraZeneca AZD1222 Clinical Study Group‡

1University of Rochester School of Medicine and Dentistry, Rochester, NY
2Rochester Regional Health, Rochester, NY
3Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases, New York, NY
4Biometrics, Late-stage development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
5Biometrics, Late-stage development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
6Walter Reed Army Institute of Research, Silver Spring, MD
7University of Washington, Seattle, WA
8Fred Hutchinson Cancer Research Center, Seattle, WA
9University of Maryland School of Medicine, Baltimore, MD
10
10 New York University Vaccine Center, New York, NY
11 HealthPartners Institute, St Paul, MN
12 Orlando Immunology Center, Orlando, FL
13 Hassman Research Institute, Berlin, NJ
14 University of California San Diego, San Diego, CA
15 Children's Mercy Kansas City, Kansas City, MO
16 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
17 Tekton Research, Austin, TX
18 Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA
19 JEM Headlands Research, Palm Beach County, FL
20 Centex Studies, McAllen, TX
21 Medpharmics LLC, Albuquerque, NM
22 John H. Stroger Jr., Hospital of Cook County, Chicago, IL
23 Department of Public Health, San Francisco, CA
24 Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear
Defense, Edgewood, MD
25 Instituto de Ciencias Biomédicas, Facultad de Medicina Universidad de Chile, Santiago,
Chile
26 Clínica Internacional Sede Lima, Lima, Perú
27 Clinical Research Partners, Richmond, VA
28 University of Vermont Larner College of Medicine and UVM Medical Center, Burlington,
VT
29 Mercury Street Medical Group, Butte, MT
30 National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD
31 Rollins School of Public Health at Emory University, Atlanta, GA
32 Infectious Diseases, Late-stage Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
33 Translational Medicine, Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca,
Gaithersburg, MD, USA
34 Infectious Diseases, Late-stage Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
35Clinical Development, Early Global Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA
36Late-stage Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
37BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

*Equal contributions
†At the time of the trial
‡Members are listed below
Contents

Supplementary Appendix........................................................................................................... 1
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine ............ 1
ASTRAZENECA AZD1222 CLINICAL STUDY GROUP (alphabetical): ............................. 6
SUPPLEMENTARY METHODS ............................................................................................. 8
    Trial Oversight ....................................................................................................................... 8
    Trial Definitions ..................................................................................................................... 8
    Full Trial Inclusion and Exclusion Criteria ........................................................................... 9
    Trial Design ......................................................................................................................... 11
    Covid-19 Qualifying Symptoms* ........................................................................................ 12
    Trial Illness and Sampling Procedures ................................................................................ 13
    Severe or Critical Symptomatic Covid-19 ........................................................................... 13
    Humoral Immunogenicity and Whole Genome Sequencing ............................................... 14
        SARS-CoV-2 Antigen Testing Assays ............................................................................ 14
        Validated Pseudovirus Neutralization Assay .............................................................. 14
        Whole Genome Sequencing of SARS-CoV-2 Samples ................................................. 14
    Statistical Analysis ............................................................................................................... 15
SUPPLEMENTARY RESULTS ............................................................................................. 20
    Clinical Hold ........................................................................................................................ 20
    Unmasking ........................................................................................................................... 20
    Efficacy ................................................................................................................................ 20
SUPPLEMENTARY ACKNOWLEDGMENTS .................................................................... 22
SUPPLEMENTARY FIGURES .............................................................................................. 26
    Figure S1. Time to First SARS-CoV-2 RT-PCR–Positive Symptomatic Illness Occurring
               after the First Dose, (Full Analysis Set, Seronegative at Baseline). ......................... 26
    Figure S2. Quantitation of SARS-Cov-2 Spike IgG Over Time (Substudy Analysis Set) 27
Figure S3. Quantitation of SARS-Cov-2 Neutralizing Antibody Over Time (Substudy Analysis Set)................................................................................................................................................28

SUPPLEMENTARY TABLES ........................................................................................................................................................................29

Table S1. Demographic and Clinical Characteristics of the Fully Vaccinated Analysis Set at Baseline* ..................................................................................................................................................................................29

Table S2. Overall Summary of Unsolicited AEs Reported Within 28 Days of Any Dose for the Safety Analysis Set .................................................................................................................................................................31

Table S3. Related Unsolicited SAEs by System Organ Class and Preferred Term for the Safety Analysis Set ........................................................................................................................................................................32

Table S4. Related Unsolicited MAAEs by System Organ Class and Preferred Term for the Safety Analysis Set ........................................................................................................................................................................33

Table S5. Related Unsolicited AESIs by Category and Preferred Term for the Safety Analysis Set ........................................................................................................................................................................36

Table S6. Summary of SARS-CoV-2 Variants by Lineage, Based on Whole Genome NGS of Saliva Samples for the Full Analysis Set, Seronegative at Baseline ............................................................................37

REFERENCES ........................................................................................................................................................................................................40
ASTRAZENECA AZD1222 CLINICAL STUDY GROUP (alphabetical):

Jeremy Ackermann, Mark S. Adams, Nathan Alderson, José O. Alemán, Mohamed S. Al-Ibrahim, David R. Andes, Jeb Andrews, Roberto C. Arduino, Martín Bäcker, Diana Badillo, Emma Bainbridge, Teresa A. Batteiger, Jose A. Bazan, Roger J. Bedimo, Jorge A. Benitez, Annette R. Bennett, David I. Bernstein, Kristin Bialobok, Rebeca Boas, Judith Brady, Angela R. Branche, Cynthia Brown, Catherine A. Bunce, Abram Burgher, Robert S. Call, Wesley Campbell, Ellie Carmody, Christopher Carpenter, Steven E. Carsons, Marvin Castellon, Mario Castro, Hannah Catan, Jennifer Chang, Mouna Gharib Chebib, Corey M. Chen, Margaret Cheng, Brian D. W. Chow, Annie Ciambruschini, Joseph P. Connor, James H. Conway, Maureen Cooney, Marcel Culin, Claudia De La Matta Rodriguez, Jon F. Dedon, Emily Degan, Michelle Dickey, Craig Dietz, Jennifer Lee Dong, Brenda Dorcely, Matthew W. Doust, Michael P. Dube, Carmel B. Dyer, Benjamin Eckhardt, Edward Ellerbeck, Evan C. Ewers, Amy Falk, Brittany Feijoo, Uriel R. Felsen, Tom Fiel, David Fitz-Patrick, Charles M. Fogarty, Stacy Ford, Lina M. Forero, Elizabeth Formentini, Doris Franco-Vitteri, Robert W. Frenck Jr., Elie Gharib, Suzanne Gharib, Rola Gharib Rucker, James N. Goldenberg, Luis H. González, Brett Gray, Rusty Greene, Robert M. Grossberg, Juan Vicente Guanira-Carranza, Alfredo Gilberto Guerreros Benavides, Clint C. Guillery, Shauna H Gunaratne, David Halpert, Holli Hamilton, William R. Hartman, Timothy J. Hatlen, Gary F. Headden, Sheryl L. Henderson, Ramin Herati, Laura Hernandez Guarin, Robin Hilder, Ken Ho, Leila Hojat, Sybil G. Hosek, Jeffrey M. Jacobson, Melanie Jay, Diane H. Johnson, Kathleen S. Jones, Edward C. Jones-López, Jessica E. Justman, Scott Kahney, Lois Katz, Melinda Katz, Daniel Kaul, Michael C. Keefer, Ashley Kennedy, Jennifer Knishinsky, Laura Kogelman, Susan L. Koletar, Angelica Kottkamp, Maryrose Laguio-Vila, Raphael J. Landovitz, Jessica L. Lee, Albert Liu, Eneyda Giuvanela Llerena Zegarra, Anna S. Lok, James Lovell, Ronald Lubelchek, John Lucai, Gary Luckasen, Annie Luetkemeyer, Njira Lucia Lugogo, Janine Maenza, Carlos Malvestutto, Robin Mason, Paul Matherne, Monica Mauri, Ryan C. Maves, Kenneth H. Mayer, Michael J. McCartney, Margaret E. McCort, M. Juliana McElrath, Meredith McNairy, Fernando L. Merino, Eric A. Meyerowitz, Carol L. Mitchell, Cynthia L. Monaco, Sauda Muhammad, Sigridh Muñoz-Gómez, Sonal Munsiff, Paul Nee, Nicole L. Nollen, Asif Noor, Claudio Nuñez Lagos, Jason F. Okulicz, Patrick A. Oliver, Jessica Ortega, Steven Palmer, Lalitha Parameswaran, Purvi Parikh, Susan Parker, Reza Parungao, Juana Rosa Pavie, Rebecca Pellett Madan, Henry Peralta, Jennifer Petts, Kristen K. Pierce, Terry L.
SUPPLEMENTARY METHODS

Trial Oversight
Training and certification were required for all site personnel responsible for completing assessments. A Protocol Safety Review team and an Independent Data Safety Monitoring Board reviewed safety data throughout the trial and potential Covid-19 cases were assessed by an independent adjudication committee that was unaware of group assignment. AstraZeneca was involved in trial design, collection, analysis, and interpretation of the data. Input was also obtained from the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, the National Institute of Health, the Covid-19 Prevention Network, and the trial Co-Chairs. Authors Ann Falsey and Magdalena Sobieszczyk developed the first manuscript draft with medical writing assistance funded by AstraZeneca.

Trial Definitions

| Term                                      | Definition                                                                                                                                                                                                 |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Increased risk of SARS-CoV-2 infection    | Adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and Covid-19, based on available risk assessment contemporaneous to enrollment (believed to be at risk/exposure) |
| Medically stable                          | A stable medical condition was defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment                                    |
| Clinical signs at rest indicative of severe systemic illness | Respiratory rate 30 or more breaths per minute; heart rate 125 or more beats per minute; oxygen saturation 93% or less on room air at sea level; or partial pressure of oxygen to fraction of inspired oxygen ratio less than 300 mmHg |
| Respiratory failure                       | Defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation                                                                            |
| Evidence of shock                         | Systolic blood pressure less than 90 mmHg, diastolic blood pressure less than 60 mmHg, or requiring vasopressors                                                                                         |
| MAAEs                                     | MAAEs were defined as AEs leading to medically-attended visits that were not routine visits for physical examination, vaccination, or illness visits such as an emergency room visit, or an otherwise unscheduled visit to or from medical personnel for any reason |
AESIs included terms identified by the Brighton Collaboration involving events associated with vaccination in general

AE, adverse events; AESIs, adverse events of special interest; Covid-19, coronavirus disease 2019; MAAEs, medically-attended adverse events; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

**Full Trial Inclusion and Exclusion Criteria**

Full inclusion criteria were:

- Adult, 18 years of age or older at the time of consent
- Increased risk of SARS-CoV-2 infection (see **Definitions**)
- Medically stable (see **Definitions**) such that, according to the judgment of the investigator, hospitalization within the trial period was not anticipated and the participant appeared likely to be able to remain in the trial through the end of protocol-specified follow-up
- Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Women of childbearing potential were required to:
  - Have a negative pregnancy test on the day of screening and on Day 1
  - Use one highly effective form of birth control for at least 28 days prior to Day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of the second dose of trial intervention.
- Women were considered of childbearing potential unless they met either of the following criteria: surgically sterilized (including bilateral tubal ligation, bilateral oophorectomy, or hysterectomy); or postmenopausal
- Capable of giving signed informed consent (or legally authorized representative able to provide consent)

Full exclusion criteria were:

- History of allergy to any component of the vaccine
- History of Guillain-Barré syndrome or any other demyelinating condition
- Significant infection or other acute illness, including fever over 100°F (over 37°C) on the day prior to or day of randomization
• History of laboratory-confirmed SARS-CoV-2 infection
• Any confirmed or suspected immunosuppressive or immunodeficient state, including asplenia
• Recurrent severe infections and use of immunosuppressant medication within the past 6 months (20 mg/kg/day or more of prednisone or its equivalent, given daily or on alternate days for 15 days or more within 30 days prior to administration of trial intervention). The following exceptions were permitted:
  o Topical/inhaled steroids or short-term oral steroids (course lasting 14 days or less)
  o Human immunodeficiency virus-positive stable participants on stable antiretroviral therapy
• History of primary malignancy except for:
  o Malignancy with low potential risk for recurrence after curative treatment (for example, history of childhood leukemia) or metastasis (for example, indolent prostate cancer) in the opinion of the site investigator
  o Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  o Adequately treated uterine cervical carcinoma in situ without evidence of disease
  o Localized prostate cancer
• Clinically significant bleeding disorder (for example, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture
• Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness, as judged by the Investigator (mild/moderate well-controlled coexisting conditions are allowed)
• Any other significant disease, disorder, or finding that may have significantly increased the risk to the participant because of participation in the trial, affect the ability of the participant to participate in the trial, or impair interpretation of the trial data
• Receipt of, or planned receipt of investigational products indicated for the treatment or prevention of SARS-CoV-2 or Covid-19
  o For participants who became hospitalized with Covid-19, receipt of licensed treatment options and/or participation in investigational treatment studies was permitted
• Receipt of any vaccine (licensed or investigational) other than licensed influenza vaccines within 30 days prior to and after administration of trial intervention
• Receipt of immunoglobulins and/or any blood products within 3 months prior to administration of trial intervention or expected receipt during the period of trial follow-up
• Involvement in the planning and/or conduct of this trial (applied to both Sponsor staff and/or staff at the trial site)
• For women only: pregnancy (confirmed with positive pregnancy test) or breastfeeding
• Had donated 450 mL or more of blood products within 30 days prior to randomization or expected to donate within 90 days of administration of second dose of trial intervention

Participant lifestyle considerations were:
• Participants were required to follow the contraception requirements as defined in the inclusion criteria
• Concomitant medications or vaccines (including over-the-counter or prescription medicines and excluding vitamins and/or herbal supplements) received by the participants at the time of enrollment or during the trial were recorded
• If diagnosed with Covid-19, participants were required to wear a biosensor, digital health device to continuously track biophysical parameters

Trial Design
For the primary endpoint, symptomatic was defined as 1 or more of the following criteria: pneumonia diagnosed by chest X-ray or computed tomography scan; oxygen saturation 94% or less on room air or requiring new initiation or escalation in supplemental oxygen; or new or worsening dyspnea/shortness of breath; or 2 or more of the following symptoms/signs: fever over 100°F or feverishness; new or worsening cough; myalgia/muscle pain; fatigue that interferes with activities of daily living; vomiting and/or diarrhea (one finding counted
toward endpoint definition); or anosmia and/or ageusia (one finding counted toward endpoint definition).

Participants who experienced 1 or more of the following Covid-19 qualifying symptoms were to contact the trial team:

**Covid-19 Qualifying Symptoms***

| Duration               | Symptom               |
|------------------------|-----------------------|
| No minimum duration    | Fever                 |
|                        | Shortness of breath   |
|                        | Difficulty breathing  |
| Present for 2 days or more | Chills               |
|                        | Cough                 |
|                        | Fatigue               |
|                        | Muscle aches          |
|                        | Body aches            |
|                        | Headache              |
|                        | New loss of taste     |
|                        | New loss of smell     |
|                        | Sore throat           |
|                        | Congestion            |
|                        | Runny nose            |
|                        | Nausea                |
|                        | Vomiting              |
|                        | Diarrhea              |

*Adapted from Centers for Disease Control and Prevention (CDC) 2020.
**Trial Illness and Sampling Procedures**

If a participant presented with Covid-19 qualifying symptom(s) on Days 1–3 post-vaccination, the nasal pharyngeal (NP) swab that was collected on Day 1 was sent for local SARS-CoV-2 RT-PCR testing. If positive, the participant was instructed to initiate illness visits. If negative, the participant continued with scheduled assessments. After Day 3 post-vaccination, a participant with Covid-19 qualifying symptoms was instructed to attend illness visit 1 where two NP swabs were collected, one for local RT-PCR testing and one for central testing. The local test was used for patient management and the central test was used to determine SARS-CoV-2 RT-PCR status. If the local RT-PCR was negative, the participant was directed to stop illness visits and resume regular follow-up visits. If positive, the participant continued with illness visits and was instructed in home collection requirements, including use of a digital health device, saliva samples, and e-Diary recordings. NP swabs for central lab RT-PCR were also collected at illness visits on Days 14, 21, and 28. In the event that the central lab PCR was not collected or was not available (i.e., lost in shipping, spoiled, etc.) then the local lab PCR result was used for endpoint determination. If the local and central PCR test results were discordant, such that the local was positive and the central was negative, the adjudication committee could consult the saliva RT-PCR result in determining whether the participant was PCR-positive.

Serum samples were collected from participants at Days 1, 29, 57, 90, 180, 360, and 730 for SARS-CoV-2 antibody testing to monitor participants for interim acquisition of asymptomatic infection. Authorized laboratories assessed serologic responses to AZD1222 by the rate of participants seroconverting from negative to positive as defined by a validated immunoassay directed at the SARS-CoV-2 spike antigen. Additional serum samples were collected in the substudy at Days 15 and 43 for immunogenicity testing. Saliva was collected during illness visits and at home to quantify duration of viral shedding on Days 1, 3, 5, 8, 11, 14, 21, and 28 of the illness.

**Severe or Critical Symptomatic Covid-19**

For this trial, severe or critical symptomatic Covid-19 was defined as laboratory-confirmed SARS-CoV-2 RT-PCR–positive symptomatic illness plus 1 or more of the following features: clinical signs at rest indicative of severe systemic illness; respiratory failure;
evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; ICU admission; or death.

**Humoral Immunogenicity and Whole Genome Sequencing**

**SARS-CoV-2 Antigen Testing Assays**

SARS-CoV-2 nucleocapsid antibodies were measured for all participants with a validated Roche Elecsys® Anti-SARS-CoV-2 nucleocapsid serology test (Covance CLS, Indianapolis, IN). A validated quantitative multiplexed electrochemiluminescent assay was used to determine responses to the spike, receptor-binding domain, and nucleocapsid SARS-CoV-2 viral antigens (PPD Vaccines, Richmond, VA). Antibody concentrations were determined in an indirect binding format on a 10-spot plate on the Meso Scale Discovery® platform. A reference standard was created by pooling pre-screened Covid-19–positive human serum samples. Test sample antibody concentrations were determined by interpolating relative light units to a standard curve generated from the serially diluted reference standard and assigned a concentration in arbitrary units (AU)/mL. Validation included precision and ruggedness, dilutional linearity, selectivity, and relative accuracy for each SARS-CoV-2 antigen.

**Validated Pseudovirus Neutralization Assay**

Neutralizing antibodies were assessed in a validated lentivirus-based SARS-CoV-2 pseudovirus assay (Monogram Biosciences, South San Francisco, CA). Pseudovirions containing luciferase and a Wuhan-Hu-1 spike protein were preincubated with serial dilutions of serum. Antibody titers are reported as the reciprocal of the serum dilution conferring 50% inhibition (ID_{50}) of pseudovirus infection. A specificity control containing a non-specific pseudovirus (for example, Avian Influenza envelope) was utilized to determine activity was specific to SARS-CoV-2. Method validation included accuracy, repeatability, intermediate precision, and linearity.

**Whole Genome Sequencing of SARS-CoV-2 Samples**

Saliva specimens were collected at clinical sites or self-collected by trial participants in Spectrum Solutions SDNA-1000 Saliva Collection Device. Saliva specimens that were assessed as positive by the TaqPath™ SARS-CoV-2 Assay (Infinity BiologiX, Piscataway, NJ) were available for next-generation sequencing by the Illumina COVIDseq Test. The first
positive specimen for each trial participant for whom a positive saliva shedding sample was available was assessed.

The analysis workflow included steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. RNA extraction was performed using the PerkinElmer chemagic™ 360 automated specimen processing system with the chemagic™ Prime Viral DNA/RNA 300 Kit H96. Complementary DNA synthesis and library preparation was performed using the Illumina COVIDSeq Test kit. Libraries were pooled, quantified, normalized, and sequenced on a NovaSeq™ 6000 Sequencing System.

Sequence files were analyzed using the Illumina DRAGEN COVIDSeq Test App in BaseSpace Sequence Hub. The COVIDSeq Test leveraged 98 amplicons to amplify SARS-CoV-2-specific sequences, and for samples with 90 or more SARS-CoV-2 amplicons detected, the DRAGEN COVIDSeq Test Pipeline generated a consensus sequence in FASTA format and performed variant calling. The Pango Lineage is reported. The COVIDSeq method was performed at Infinity BiologiX in Piscataway, NJ, USA. The COVIDSeq assay workflow for SARS-CoV-2 strain determination was validated for saliva samples as a biospecimen.

**Statistical Analysis**

Safety analyses were based on the safety analysis set, defined as all participants who received 1 or more dose of trial treatment and grouped based on actual treatment obtained. Adverse events (AE) severity was graded according to a revised US Food and Drug Administration toxicity grading guidance and coded using the Medical Dictionary for Regulatory Activities (MedDRA, version 23.1). Safety data were analyzed descriptively.

All efficacy analyses were based on the fully vaccinated analysis set (FVAS) unless otherwise specified, which included all participants who were SARS-CoV-2 seronegative at baseline, received two doses of trial intervention, and who remained in the trial 15 days or more after their second dose without having had a prior confirmed SARS-CoV-2 RT-PCR–positive infection. A blinded, independent, efficacy adjudication committee reviewed relevant data of potential cases for Covid-19–related efficacy endpoint evaluations. Efficacy analyses included only illnesses independently adjudicated as Covid-19 events.
A Poisson regression model with robust variance\(^3\) adjusted for follow-up time, was used as the primary efficacy analysis model to estimate the relative risk of the incidence of symptomatic infection between the AZD1222 and placebo groups. The model contained the trial group and age group at the time of informed consent (≥18 to <65 years, versus ≥65 years) as covariates. The logarithm of the participant’s corresponding monitoring period at risk, starting from 15 days or more after the second dose of trial intervention up to either the event, data cut-off, the date of unmasking or EUA vaccine, date of early withdrawal or the date of a SARS-CoV-2 RT-PCR–positive infection not meeting the endpoint definition, whichever occurred first, was used as an offset variable in the model to adjust for participants having different exposure times during which the events occurred. The null hypothesis used for the primary efficacy endpoint was that vaccine efficacy is equal to 30%.

Regardless of cause, all deaths were submitted to the adjudication committee for independent blinded review and categorized as Covid-19-related or not. As such, all deaths adjudicated as related to Covid-19 were included as a primary efficacy endpoint event and deaths adjudicated as not related to Covid-19 were treated as intercurrent events and therefore censored at the date of death. Although non-Covid-19 deaths are a competing risk, given that all deaths were independently adjudicated and there was no imbalance between groups censoring at the date of non-Covid death would not be expected to impact the results.

This analysis was repeated for the secondary endpoints of symptomatic Covid-19 regardless of prior SARS-COV-2 infection, symptomatic Covid-19 according to the CDC criteria, Covid-19 related Emergency Department visits and post-treatment response, as well as the exploratory endpoint of Covid-19-related hospitalizations. For the key secondary endpoint of severe or critical Covid-19, a stratified exact Poisson regression model was used, with age group at the time of informed consent (≥18 to <65 years, or ≥65 years) as the strata. The number of events for each combination of treatment and strata was used as the response variable and the logarithm of total number of participants for each combination of treatments and strata was used as an offset variable in the model. Given that the AZD1222 group had 0 events, the maximum likelihood estimate for the relative risk was zero, corresponding to a vaccine efficacy of 100%, and the 1-sided 97.5% confidence interval was presented. A supportive analysis of the time to primary efficacy endpoint was performed using a Cox proportional hazards model, where the vaccine efficacy was estimated as 1- hazard ratio.
(HR), where HR was the ratio of the incidence in the AZD1222 group relative to the incidence in the placebo group expressed as a percentage. In addition, a sensitivity analysis using a multiple imputation approach to evaluate the robustness of the primary analysis of the primary endpoint, the missing outcome for participants with truncated follow-up (eg, trial withdrawal, lost to follow-up, death not caused by SARS-CoV-2, unmasking or EUA vaccination) prior to reaching the data cut-off without a primary endpoint event was imputed by age group stratum using the event rate per treatment group under the assumption of missing at random. The imputation was carried out using SAS PROC MI (Monotone Logistic Regression Method) and was repeated 20 times. SAS PROC MIANALYZE was used to combine inferences from the 20 completed datasets.

For the primary efficacy analysis, approximately 150 events meeting the primary efficacy endpoint definition were required across the AZD1222 and placebo groups within the population of participants who were seronegative at baseline to detect a vaccine efficacy of 60% with >90% power. These calculations assumed an observed attack rate of 0.8% and were based on a two-sided test, where the lower bound of the two-sided multiplicity-adjusted confidence interval (CI) for vaccine efficacy is required to be >30% with an observed point estimate of at least 50%. Sample size calculations accounted for an interim analysis at approximately 75 events (when approximately 50% of the total amount of statistical information is available) and a primary analysis at approximately 150 events, the timing of which were driven by the number of events in the trial, assuming minimal loss to follow-up as it was anticipated that participants would remain engaged in the trial. A Lan-DeMets alpha-spending function was used to account for multiplicity across the interim and primary analyses such that the overall Type I error was controlled at 5%. If exactly 75 cases were analyzed at the interim and 150 cases at the primary analysis, the alpha levels would have been, 0.31% and 4.9%, respectively. Given the interim analysis was actually carried out with 141 cases, in accordance with the pre-planned Lan-DeMets alpha-spending function, the alpha level used for the interim was 4.16%. Given the criteria for evidence of efficacy were met at the interim analysis, the primary analysis was carried out at the nominal 5% alpha level.
The key secondary endpoints were tested at the adjusted significance level using hierarchical fixed-sequence testing in the order below. If the two-sided multiplicity-adjusted CI was >0%, then analysis proceeded to the next endpoint:

1. Key Secondary Endpoint 1: Incidence of the first case of SARS-CoV-2 RT-PCR–positive symptomatic illness occurring 15 days or more after the second dose of trial intervention regardless of evidence of prior SARS-CoV-2 infection
2. Key Secondary Endpoint 2: Incidence of the first case of SARS-CoV-2 RT-PCR–positive severe or critical symptomatic Covid-19 occurring 15 days or more after the second dose of trial intervention
3. Key Secondary Endpoint 3: Incidence of Covid-19-related Emergency Department visits occurring 15 days or more after the second dose of trial intervention.
4. Key Secondary Endpoint 4: Incidence of the first post-treatment response (negative at baseline to positive post treatment with trial intervention) for SARS-CoV-2 nucleocapsid antibodies occurring 15 days or more after the second dose of trial intervention

A primary efficacy analysis was planned to be conducted when approximately 150 events meeting the primary efficacy endpoint definition had been reported across the AZD1222 and placebo groups within the population of participants who were seronegative for SARS-CoV-2 at baseline. The interim analysis data package (with the data cut-off date of February 17, 2021) was delivered by the independent statistical group to the Data Safety Monitoring Board (DSMB) on March 11, 2021. Following independent review and additional analyses, on March 17, 2021, the DSMB determined that the interim analysis criteria had been met for the primary efficacy endpoint and the trial team could move forward with the full interim analysis. A decision was therefore made to proceed with unblinding of the trial results as of March 18, 2021. Based on data accumulated up to March 17, 2021, there were >150 adjudicated primary endpoint events in the FVAS. Given >150 adjudicated primary endpoint events had been reached at this time, the primary analysis was conducted. A data cut-off date of March 5, 2021, corresponding to the start date of the last adjudicated event meeting the primary endpoint definition, was therefore applied to the unblinded data transfer, received on March 19, 2021. An initial primary analysis was conducted in parallel to the adjudication of 14 outstanding potential cases. Following confirmation that all events prior to the data cut-off
had been fully adjudicated, the data analysis was refreshed and updated to ensure that all cases were appropriately included in the data set being reported.

Subgroup analyses were performed on the following groups where sufficient cases were observed:

- Age group at informed consent (≥18 to <65 years and ≥65 years)
- Sex
- Serostatus at baseline (negative and positive), where seropositive is defined by a positive nucleocapsid antibody level as measured by Roche Elecsys® Anti-SARS-CoV-2 serology test
- Race
- Ethnicity
- Country of enrollment
- Covid-19 coexisting conditions at baseline

A further secondary endpoint of the incidence of the first case of SARS-CoV-2 RT-PCR–positive symptomatic illness occurring 15 days or more after the second dose of trial intervention using CDC criteria was analyzed using the symptoms presented as “qualifying symptoms” above. For this endpoint, participants were only required to have qualifying symptoms for 1 or more days.
SUPPLEMENTARY RESULTS

Clinical Hold
On September 9, 2020, the trial was placed on clinical hold due to an event of transverse myelitis reported in a different AZD1222 clinical trial. After a review of the event and all available safety data, the US Food and Drug Administration deemed it was safe to lift the clinical hold on October 23, 2020 and the trial resumed on October 28, 2020. Enhanced safety monitoring and reporting procedures were implemented for the AZD1222 trials. As a consequence of this hold ~800 participants had a dosing interval >4 weeks and are included in the safety analysis set as randomized and are included in the FVAS where meeting the criteria for inclusion.

A total of 775 participants (2.4%) in the safety analysis set were impacted by the clinical hold and received their second dose outside of the planned 28-day window.

Unmasking
Due to the availability of other Covid-19 vaccines under EUA, trial participants eligible for receipt of a vaccine were unmasked beginning December 14, 2020. Overall, data from 6100 (34.5%) participants in the FVAS fully vaccinated analysis set were censored at the time of unmasking in the AZD1222 group, and 3253 (38.0%) in the placebo group.

Efficacy
Due to the urgency of data dissemination required during the pandemic setting, the initial estimated vaccine efficacy using the primary dataset, which did not include 14 potential cases that were pending adjudication, was publicly disclosed (76.0%, 95% CI 67.6–82.2, P<0.001). Once adjudication of all events before the data cut-off (March 5, 2021) was complete, 203 symptomatic Covid-19 events met the case definition of the primary endpoint and were included in the updated primary analysis for the fully vaccinated analysis set (AZD1222 n=17,662, placebo n=8550) (Figure 1). All following presented analyses are based on the updated primary analysis of the censored group.

The estimated vaccine efficacy for incidence of first SARS-CoV-2 RT-PCR–positive symptomatic illness occurring post first dose of trial intervention among participants in the full analysis set who were SARS-CoV-2 seronegative at baseline was 54.5% (95% CI 46.5–
61.3) based on 287 cases out of 20,302 (1.4%) in the AZD1222 group and 303 cases out of 9,997 (2.9%) in the placebo group. The cumulative incidence of first SARS-CoV-2 RT-PCR–positive symptomatic illness following the first dose of AZD1222 is shown in Figure S1.

Estimated vaccine efficacy against infection was 64.3% (95% CI 56.1–71.0, P<0.001), with 156 seroconversions (0.9%) in the AZD1222 and 202 seroconversions (2.4%) in the placebo group. As a result of the 2:1 randomization, the total follow-up time was 2000 person years for AZD1222 and 900 person years for placebo. Incidence rate (cases per 1000 person-years) was 76.9 for AZD1222 and 215.4 for placebo participants.

Further investigations to determine the potential impact of circulating SARS-CoV-2 variants on AZD1222 vaccine efficacy are ongoing.
SUPPLEMENTARY ACKNOWLEDGMENTS
The authors would like to thank Sally Abare, Athina Agbayani, Jenny Ahn, Justin Akin, Gumana Ali, Mahnoor Ali, Jeffrey Allard, Cat-Dancing Alleyne, Jocelyn Allgood, Christy Altman, Ivanna Alvarez, Rubi Arias, Sonya Arzola, Margarita Ashkinazi, Breanne Baez, Ted Baker, Luis Ballon, Alexandra Banks, Elaina Barker, Elizabeth Barker, Vanessa Barrientos, Christina Barron, Fawzy Barry, Christine Batchelder, James Battle, Steve Bean, John Beaton, Daniel Beaver, Megan Beaver, Hannah Becker, Jennifer Bedard, Maria Begoña Carroza, Elleny Benitez, Aneesh Benoy, Joan Bertolet, Shanae Black, Alejandra Blas, Megan Bledsoe, Jeffrey Bloch, Dana Blyth, Nathan Boggs, Kelly Bojan, Sara Boland, Silvana Botero, Hamid Bouiri, Adrianna Boulin, Susan Bravo, Diane Bresch, Sawyer Bittner Bressler, Jasmine Briscoe, Bernadette Brooks, Alexis Brown, Eugene Brown, Susan Brown, Janet Brunader, Shea Buckley, Cosette Burian, Bobbi Burwell, Bart Buurman, Bruce Callahan, Mary Cambou, Brenderia Cameron, Michelle Campbell, Christhian Cano-Guerra, Ana-Maria Capote-Colmenares, Maria Carbajal, Marya Carmolli, Nicole Carter, Yvonne Carter, Lori Caruso, Amy Chamberlain, Catherine Chatowsky, Ari Chavez, Pedro Chavez, Camila Cheater, Edwin Chen, Nikhit Chimalakonda, Madhuchhanda Choudhary, Andrew Chung, Katie Clerkin, Bert Cole, Carol Cole, Limone Collins, Shelley Collins, Jean Comstock, James Conway, Joie Cooper, Katya Corado, Ramiro Correa, April Correll, Michele Corriveau, Louisa Coughlin, Stacy Cox, Whitney Crebase, Mary Criddle, Nicole Crockford, Debbie Crownover, Samantha Cruz, Llazar Cuko, Emerald Culbreath, Meriles Curry, Vanessa Curtis, Betsy Cutler, Jonida Dake, Gina Daniel, Janine Danko, Janet Dargon, Lauren Davey, Brianna David, Jessica Elizabeth-Ann Davis, Stephanie Davis, Tamia Davis, Kristy Delaney, Stephanie Deleon, Patty DeMarais, Carmen DeMarco, Gina Demilt, Joy Denham, Thomas Denny, Dennis Dentoni-Lasofsky, Iveth Diaz, Mary Dinan, Lucy Dinh, Tsetan Dolqar, Julian Dormitzer, Marcia Dunham, Janet DuPont, Jay Dwyer, Shakir Edwards, Anthonia Egbedeju, Lori Elliot, Michelle Enerson, Hector Erazo, Juanita Erb, Matthew Escamilla, Janet Estrada, Divina Fanning, Jessica Faraci, Anita Farhi, Emily Farrell, Candance Faye, Ana Maria Fernandez, Jennifer Fernandez, Aaron Figueroa, Jennifer Fimbres, Rossi Fish, Fiona Fitzgerald, Julia Fleming, Chantel Fletcher, Tammy Flore, Jayline Flores, Patrick Flume, Doreen Francis, Marie Francis, Kathy Franco, Lizbeth Franco, Hilda Futterman, Kia Gallagher, Gabriela Gallardo, Cesar Gamarra, Anuradha Ganesan, April Garcia, Roy Garcia, Sandi Garner, Nancy Garrett-Mead, Samantha Gatewood, Jennifer Gedz, Emilie Geesey,
Isabella Gharib, Jonatan Gioia, Jennifer Giordano, Amber Gipson, Heather Givans, Todd Gleeson, Rachel Goff, Elvira Gomez, Yovelín Gomez, Amanda Gonzales, Kathy Gonzales, Mireya I. Gonzalez, Neydi Gonzalez, Rafael Gonzalez, Amalea Gray, Jess Gray, Gabriella Green, Tondria Green, David Greenstein, Rachel Groff, Mario Guerrero, Jill Guilfoile, Ramiro Gutierrez, Olivia Guzman, Emma Gyurisin, Chase Hall, Natalie Semaan Hall, Christine Hamby, Melinda Hamer, MJ Hamersma, Songhee Han, Lynn Harrington, Emily Hart, Byron Hauser, Megan Helf, Brooklyn Henderson, Nora Henderson, Suzanne Hendler, Megan Hendrick, Lori Hendrickson, Steven Hendrickx, Waylon Henggeler, Tammy Herbert, Megan Hinton, Michael Hirsch, Shelley Hoch, Karma Hodge, Megan Hodges, Barbara Hoeben, Michelle Hoes-Stevens, Dianna Hoeth, Donna Hoffman, Risa Hoffman, Abdonnie Holder, Devin Holland, Johnathon Holmes, Theresa Howard, Glen Huang, Sherry Huber, Kim Huck, Brenda Hudson, Jack Hutter, Sunny Hyeun Young, Juan Ibarra, Jr., Shanna Igbinoba, Christine L. Inguglia, Damian Inlall, Zeeshan Iqbal, Vidya Iyer, Fatima Jackson, Mortrea Jackson, Rachel Jackson, Jana L. Jacobs, Genice Jacques, Umair Jarral, Abel Jarrell, Thomas Jenkins, Donna Jennings, Mohit Jindal, Paul Johnson, Roderick Johnson, Russell Johnson, Ethan Jones, Macie Jones, Reny Jose, Sajumon Joseph, samania Jovin-Doherty, Chris Jozwick, Kristin Kahla, Ann Kahn, Ayesha Kamil, Trishala Karmacharya, Ashley Katin, Vineet Kaur, Nazanin Kavehfar, Arati Kelekar, Kelly Keller, Pamela Kemp, Ashley Kennedy, Taimur Khan, Jamie Kidd, Tiffany Kim, Liliana Kim, Patrick Kingsley, Emily Ko, John Koerber, Kanika Koirala, Michael Koren, Andrew Korman, Lydia Kosovich, Jessica Kraft, Douglas Krakower, Beth Kring, Luz Kumpel, Stephanie Kung, Christopher Kurien, Taryn Kurosawa, Rebecca Lai, Loni Lampkins, Brook Land, Christopher Lane, Sinclair Lao, Eunice Larbi, Derek Larson, Heycha-Rosada Lebron, Andy Lee, Rachel Lee, Jesse LePage, Karen Lepuschenko, Grace Lioue, Sylvia Livas, Jay Loeffel, Esteban Loeca, Carolina Lopez, Nancy Lopez, Ruben Lopez, Raul Louzao, Carter Lovvorn, Kimberly Luebbers, Jody Luke, Pablo Lundie, Patricia Lutton, Kare Lyche, Caroline Lyon, Patrick MacDonald, Caitlin MacGregor, Edna Machain, Megan MacIsaac, Michelle Mack, Barbara Mahoney-Walker, Vivian Maldonado, Jason Malenfant, Bipin Malla, Meena Malhotra, Hannah Mansky, Elsie Marius, Lisa Mark, Natalie Marks, Dannae Martin, Joyce Martin, Sharli Maxwell, Kenneth H. Mayer, Michelle Mayon, Michelle McCart, Sarah McCartney, Jemima Mccluskey, Quinola McCullough, Alison McLoughlin, Deborah McMahon, Amy McManus, Cheryl McNeal, Raymond McPherson, Tegan Mead, Patricia V. Medina, Rita Mennuti, Allison
Mentzos, Joel Mermis, Morgan Messeder, Maggie Messplay, Nicole Meyer, Alicia Miggins, Cecilia Mikita, Ashley Miles, Kelly Minus, Alfiya Mityukova, Yassir Mohamed, Jay Montgomery, Tony Moody, Akeem Moore, Joan Morris, Ellen Morrison, Darren Morrow, Alexandra Moss, Saba Mostafavi, Lisa Motowski, Ryan Muench, Karen Mullen, Cyrus Munguti, Christina Murillo, Madison Murphy, Angela L. Myers, Keila Najera, May Navarra, Iris Navarro, Blessing Ndukwu, Alina Neganova, Nancy Neilan, Taylor Nelson, Eli Nevel-Tyler, Katie Newman, Lorna Nguutu, Jeanette M. Nichols, Eric Nieves, Inja Noh, Leila Noori, Viviana Noriega, Sarah Northup, Erin Nowicki, Diane Obrien, Michelle Okulicz, Katy Oldach, Jurumay Oliva, Ellie K. Onstott, Alejandra Ornelas, Ixchell Ortiz Estes, Veronika Ovchinnikova, Laura Pace, Richard Pack, Lillian Pao, Korin Parrella, Joanna Partida, Sarah Pastolero, Ginger Patel, Priti Patel, Eddie Patino, Cindy Pau, Yestial Paul, Michael Peasley, Marilyn Pena, Margaret Pendzich, Danielle Perkins, Patricia Peters, Anthony Peterson, Diane Petrie, L. Jennifer Phillip, Wey Ling Phuah, Pie Pichetsurnthorn, Joanna Pierce, Patricia Pizarro-Franchino, Carolina Ponce-Olmos, Ashley Portillo Recinos, Logan Posey, Kelvin Powell, Kimberly Powell, Amy Prahl, Angela Pratt, Kristie Price, Christopher Prihoda, Amol Purandare, Carlos Raffo, Crystal Ramirez, Stacy Ranz, Christine Reaser, Rashaunna K. Redd, Kondal Reddy, Dorothy Rego, Rose Ressner, Kristine Reynaldo, Cynthia Reynolds, Avril Richards, Kyle W. Richards, Christa Riekert, MontaQ'ue Rios, Jason Rippe, Adreanne Rivera, Isabel Rivera, Paul Robben, Alexis Robinson, Sara Robinson, , Nimna Rodrigo, Bryan Rowe, Rafael Ruiz-Martinez, Beth Rutherford, John Paul Ryan, Beulah P. Sabundayo, Elizabeth Salazar, Marie Samanovic-Golden, MaryBeth Sampson, Brenda Sanchez, Maria Verónica Sánchez, Sarahmay Sanchez, Yajaira Sanchez, Ellen Zoe Sanders, Ruth Santos, Madalyn Saporito, Joseph Sarocie, Julie Sarotte, Brittany Satterfield, Marie Sauer, Andreas Schmid, Virginia Schmidt, Christine Scholtz, Amanda Schonhoff, Tiffany Schwasinger-Schmidt, Natalie Semaan Hall, Doris Sepe, Ian SerVaas, Cedar Sexton, Sadia Shaik, Ian Shannon, Mahima Sharma, Marc Shay, Evelyn Shea, Kipa Sherpa, Phorum Sheth, Christina Shin, Nancy Sickel, Andrea Silva, Dawd Siraj, Anne Skinner, Justin Skrzynski, Tamara Small, Jacob Smith, Kelsey Smith, Lisa Smith, Peggy Smith, Jorge Soler, Angel Solorzano Vega, Rita Sondengam, Karishma Sookraj, Tatum Soto, Alexis Southwell, Mindy S. Spano, Paige Stancle, Trish Steele, Elisabeth Steigelman, Aaron Stirling, Brianne Stockman, Victoria Stouffer, Rachel Stringer, Laura Stuecher, Nikolina Sulikowski, Janine Sullivan, Nana Sylla, Christine Tanna, Cindi Temblador, Danielle Tenney, Christine Terraciano,
Meseret Tesfamariam, Ilyas Tezekbaev, Tanisha Thakurdeen, Blair Thedinger, Brynne Thompson, Joanne Thurber, Gayani Tillekeratne, Maria T. Timoney, Kelly Toledo Servin, Elisa Toma, Brooke Travis, Laurie Trevino, Eric Trigg, Michele Troiano, Caroline Trujillo, Catherine Tsiakaros, Caroline Turner Nagle, Crystal Tyler, Stefanie Uechi, Leticia U. Froix, Glen VanDeBogart, Avon Vargas, Sergio-Ignacio Vargas-Serrano, Shannon Varner, Alicia Vasile, Rhythm Vasudeva, Cassandra Ventrone, Lisa Vergos, Nia Vorhees, Julia Wagner, Theresa Wagner, John Walker, Tracey Walsh-Chocolaad, Gregory Wang, Jonathan Washington, Marjorie Weiman, Renee Weinman, Jenny Wendell, Sydney West, Chiquita West, Radica West, Sunday Whipkey, Lacey White, Diandra Williams, Jimmy P. Wilson, Vicki Wilson, Sophia Wiltse, Mallory Witt, Jessica Wong-Flores, Deirdre Won-Short, Daniel Woodland, Christopher Woods, Janet Wootton, Sherry Yeisley, Heekoung Youn, Meredith Young, Patricia Young, Jiawen Yu, Clifford Yut, John Zaccardelli, Erica Zagaja, Corina Zamora, Jasmine Zapata, and Ana Zepeda-Gutierrez for their contributions.
SUPPLEMENTARY FIGURES

Figure S1. Time to First SARS-CoV-2 RT-PCR–Positive Symptomatic Illness Occurring after the First Dose, (Full Analysis Set, Seronegative at Baseline).

The time to event was calculated as: (date of first SARS-CoV-2 RT-PCR–positive test occurring post first dose) – (date of first dose of trial intervention) + 1. For censored participants, the censoring time was from date of first dose of trial intervention to last time observed prior to data cut-off (March 5, 2021). Cumulative incidence of Covid-19 estimated using Kaplan-Meier method.

Tick marks indicate censored data.

Covid-19, coronavirus disease 2019; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure S2. Quantitation of SARS-Cov-2 Spike IgG Over Time (Substudy Analysis Set)

The box denotes IQR, the line inside the box denotes median, the marker inside the box is the geometric mean. Any points >1.5×IQR from the box were considered outliers and are not displayed. The whiskers that extend from the box indicate the minimum and maximum after removing the outliers. Boxplots are created using the log-normal distribution. D1 is the last non-missing value taken prior to the first dose. Titer values measured as <LLoQ (33 AU/mL) were imputed to a value that is half of the LLoQ. Titer values measured as >ULoQ (2,000,000 AU/mL) were imputed at the ULoQ value.

AU, arbitrary units; D, day; IgG, immunoglobulin G; IQR, interquartile range; LLoQ, lower limit of quantification; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ULoQ, upper limit of quantification.
The box denotes IQR, the line inside the box denotes median, the marker inside the box is the geometric mean. Any points >1.5×IQR from the box were considered outliers and are not displayed. The whiskers that extend from the box indicate the minimum and maximum after removing the outliers. Boxplots were created using the log-normal distribution. D1 is the last non-missing value taken prior to the first dose. Titer values measured as <LLoQ (40 ID\textsubscript{50}) were imputed to a value that is half of the LLoQ. Titer values measured as >ULoQ (787,339 ID\textsubscript{50}) were imputed at the ULoQ value.

D, day; ID\textsubscript{50}, inhibitory dilution (50%) IQR, interquartile range; LLoQ, lower limit of quantification; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ULoQ, upper limit of quantification.
Table S1. Demographic and Clinical Characteristics of the Fully Vaccinated Analysis Set at Baseline

| Characteristic                              | AZD1222 (N=17,662) | Placebo (N=8550) | Total (N=26,212) |
|---------------------------------------------|---------------------|------------------|------------------|
| **Age – yr†**                               |                     |                  |                  |
| Mean                                        | 49.8±15.7           | 49.9±15.7        | 49.9±15.7        |
| Median                                      | 51.0                | 51.0             | 51.0             |
| Range                                       | 18–99               | 18–91            | 18–99            |
| **Age group – no. (%)**                     |                     |                  |                  |
| ≥18 to 64 yr                                | 13,966 (79.1)       | 6738 (78.8)      | 20,704 (79.0)    |
| ≥65 yr                                      | 3696 (20.9)         | 1812 (21.2)      | 5508 (21.0)      |
| **Sex – no. (%)**                           |                     |                  |                  |
| Male                                        | 9922 (56.2)         | 4829 (56.5)      | 14,751 (56.3)    |
| Female                                      | 7740 (43.8)         | 3721 (43.5)      | 11,461 (43.7)    |
| **Hispanic or Latinx ethnic group – no. (%)‡** |                 |                  |                  |
| No                                          | 13,351 (75.6)       | 6370 (74.5)      | 19,721 (75.2)    |
| Yes                                         | 4035 (22.8)         | 2064 (24.1)      | 6099 (23.3)      |
| Not reported                                | 238 (1.3)           | 106 (1.2)        | 344 (1.3)        |
| Unknown                                     | 38 (0.2)            | 10 (0.1)         | 48 (0.2)         |
| **Race or ethnic group – no. (%)§**         |                     |                  |                  |
| White                                       | 14,011 (79.3)       | 6755 (79.0)      | 20,766 (79.2)    |
| Black or African American                   | 1401 (7.9)          | 706 (8.3)        | 2107 (8.0)       |
| Asian                                       | 747 (4.2)           | 352 (4.1)        | 1099 (4.2)       |
| American Indian or Alaska Native            | 744 (4.2)           | 373 (4.4)        | 1117 (4.3)       |
| Multiple                                    | 421 (2.4)           | 202 (2.4)        | 623 (2.4)        |
| Native Hawaiian or other Pacific Islander   | 50 (0.3)            | 14 (0.2)         | 64 (0.2)         |
| Not reported                                | 207 (1.2)           | 110 (1.3)        | 317 (1.2)        |
| Unknown                                     | 81 (0.5)            | 38 (0.4)         | 119 (0.5)        |
| **Country – no. (%)**                       |                     |                  |                  |
| United States                               | 15,435 (87.4)       | 7443 (87.1)      | 22,878 (87.3)    |
| Chile                                       | 1360 (7.7)          | 672 (7.9)        | 2032 (7.8)       |
| Peru                                        | 867 (4.9)           | 435 (5.1)        | 1302 (5.0)       |
| **Coexisting conditions – no. (%)¶**        |                     |                  |                  |
| Any coexisting condition at baseline        | 10,376/17,661 (58.8)| 5105/8550 (59.7) | 15,481/26,210 (59.1) |
| History of obesity‡                         | 4735/17,661 (26.8)  | 2387/8550 (27.9) | 7122/26,210 (27.2) |
| High blood pressure                         | 4712/17,661 (26.7)  | 2262/8550 (26.5) | 6974/26,210 (26.6) |
| History of smoking                          | 3359/17,661 (19.0)  | 1655/8550 (19.4) | 5014/26,210 (19.1) |
| Asthma                                      | 1727/17,661 (9.8)   | 890/8550 (10.4)  | 2617/26,210 (10.0) |
| Type 2 diabetes                             | 1228/17,661 (7.0)   | 662/8550 (7.7)   | 1890/26,210 (7.2) |
### Table 1: Coexisting Conditions (Number/Total (Percentage))

| Condition                                      | Number/Total (Percentage) |
|------------------------------------------------|---------------------------|
| Serious heart conditions                       | 567/17,661 (3.2)          |
| Liver disease                                  | 268/17,661 (1.5)          |
| COPD                                           | 238/17,661 (1.3)          |
| Cerebrovascular diseases                       | 173/17,661 (1.0)          |
| Chronic kidney disease                         | 129/17,661 (0.7)          |
| Type 1 diabetes                                | 100/17,661 (0.6)          |
| Thalassemia                                    | 29/17,661 (0.2)           |
| Scarring in the lungs: pulmonary fibrosis      | 28/17,661 (0.2)           |
| Dementia                                       | 6/17,661 (<0.1)           |
| Sickle cell disease                            | 5/17,661 (<0.1)           |
| Lower immune health due to solid organ         | 5/17,660 (<0.1)           |
| Cystic fibrosis                                | 0/17,661                  |

*Plus-minus values are mean ±SD. Data shown are from the fully vaccinated analysis population. Numbers are based on trial intervention actually received. COPD denotes chronic obstructive pulmonary disease.*

†Age reflects the age at the date of signed informed consent.

‡Race and ethnic group were reported by the participant. The same questions and categories used to determine participant race and ethnic group were used for all countries and sites. American Indian includes participants who indicated they were South American and participants who were indigenous to Peru. Multiple includes participants who reported that they were of more than one race.

§Percentages for coexisting conditions were calculated on the basis of participants with available data.

‖Obesity is a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) greater than 30.
## Table S2. Overall Summary of Unsolicited AEs Reported Within 28 Days of Any Dose for the Safety Analysis Set

|                          | AZD1222 (N=21,587) |                      | Placebo (N=10,792) |                      |
|--------------------------|---------------------|----------------------|---------------------|----------------------|
|                          | No. patients (%)    | No. events           | No. patients (%)    | No. events           |
| Any AE                   | 8771 (40.6)         | 17,491               | 3201 (29.7)         | 6047                 |
| Any AE related to trial intervention | 6238 (28.9) | 10,912               | 1525 (14.1)         | 2563                 |
| Related AE – Mild        | 4994 (23.1)         | 9287                 | 1291 (12.0)         | 2266                 |
| Related AE – Moderate    | 1198 (5.5)          | 1574                 | 220 (2.0)           | 283                  |
| Related AE – Severe      | 46 (0.2)            | 51                   | 14 (0.1)            | 14                   |
| Any AE Grade 3 or higher | 225 (1.0)           | 267                  | 116 (1.1)           | 138                  |
| Any non-serious AE       | 8731 (40.4)         | 17,372               | 3180 (29.5)         | 5984                 |
| Any SAE                  | 101 (0.5)           | 119                  | 53 (0.5)            | 59                   |
| Any SAE related to trial intervention | 1 (<0.1) | 1                   | 1 (<0.1)            | 1                    |
| Any AE with outcome of death, entire trial* | 7 (<0.1) | 7                   | 7 (<0.1)            | 9                    |
| Related AEs with outcome of death | 0              | 0                    | 0                   | 0                    |
| AEs leading to discontinuation from trial intervention | 266 (1.2) | 276                 | 162 (1.5)           | 163                  |
| Related AEs leading to trial discontinuation | 22 (0.1) | 31                  | 7 (<0.1)            | 7                    |
| Any AE leading to discontinuation from trial | 3 (<0.1) | 3                   | 5 (<0.1)            | 5                    |
| Any MAAE                 | 1288 (6.0)          | 1649                 | 632 (5.9)           | 830                  |
| Any AESI                 | 442 (2.0)           | 469                  | 319 (3.0)           | 346                  |
| Any AESI related to trial intervention | 58 (0.3)   | 66                   | 26 (0.2)            | 34                   |

Multiple events in the same category are counted only once for that category for number of participants. Events in 1 or more category are counted once in each applicable category. Includes AEs with an onset date on or after the day of first dose for the applicable reporting period. Data presented are pooled values for AEs reported within 28 days of any dose. SAEs, MAAEs and AESIs are reported through trial completion or withdrawal.

*No. deaths (%), no. events that led to the outcome of death during the entire trial. One patient may have experienced more than one event that led to death. AEs with an outcome of death in the AZD1222 group were overdose (n=2), death (unspecified) (n=1), toxic shock syndrome (n=1), accident (n=1), road traffic accident (n=1), and toxicity to various agents (n=1). AEs with an outcome of death in the placebo group were Covid-19 pneumonia (n=2), cardiac arrest (n=1), death (unspecified) (n=1), septic shock (n=1), diabetic ketoacidosis (n=1), hemorrhagic transformation stroke (n=1), ischemic stroke (n=1), and asphyxia (n=1).

AE, adverse event; AESI, AE of special interest; Covid-19, coronavirus disease 2019; MAAE, medically-attended AE; SAE, serious AE; SD, standard deviation.
Table S3. Related Unsolicited SAEs by System Organ Class and Preferred Term for the Safety Analysis Set

|                                      | AZD1222 (N=21,587) | Placebo (N=10,792) |
|--------------------------------------|---------------------|--------------------|
|                                      | No. patients (%)    | No. events         | No. patients (%) | No. events |
| **Participants with 1 or more related SAE** | 1 (<0.1)           | 2                   | 2 (<0.1)        | 2          |
| **Ear and labyrinth disorders**       | 0                   | 0                   | 1 (<0.1)        | 1          |
| Neurosensory hypoacusis               | 0                   | 0                   | 1 (<0.1)        | 1          |
| **Eye disorders**                     | 0                   | 0                   | 1 (<0.1)        | 1          |
| Optic ischemic neuropathy             | 0                   | 0                   | 1 (<0.1)        | 1          |
| **Nervous system disorders**          | 1 (<0.1)            | 2                   | 0               | 0          |
| Chronic inflammatory demyelinating polyradiculoneuropathy | 1 (<0.1)            | 1                   | 0               | 0          |
| Hypoesthesia                          | 1 (<0.1)            | 1                   | 0               | 0          |

SAE, serious adverse event.
Table S4. Related Unsolicited MAAEs by System Organ Class and Preferred Term for the Safety Analysis Set

| MAAE                                                                 | AZD1222 (N=21,587) | Placebo (N=10,792) |
|---------------------------------------------------------------------|---------------------|---------------------|
|                                                                     | No. patients (%)    | No. events          | No. patients (%)    | No. events          |
| **Participants with 1 or more related MAAE**                        | 78 (0.4)            | 112                 | 27 (0.3)            | 40                  |
| **Cardiac disorders**                                               |                     |                     |                     |                     |
| Palpitations                                                       | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Tachycardia                                                        | 1 (<0.1)            | 1                   | 0                   | 0                   |
| **Ear and labyrinth disorders**                                     |                     |                     |                     |                     |
| Tinnitus                                                           | 2 (<0.1)            | 2                   | 0                   | 0                   |
| Vertigo                                                            | 1 (<0.1)            | 1                   | 1 (<0.1)            | 1                   |
| Neurosensory hypoacusis                                            | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Sudden hearing loss                                                | 0                   | 0                   | 1 (<0.1)            | 1                   |
| **Eye disorders**                                                  |                     |                     |                     |                     |
| Eye swelling                                                       | 0                   | 0                   | 2 (<0.1)            | 2                   |
| Optic ischemic neuropathy                                          | 0                   | 0                   | 1 (<0.1)            | 1                   |
| **Gastrointestinal disorders**                                      |                     |                     |                     |                     |
| Diarrhea                                                           | 3 (<0.1)            | 3                   | 3 (<0.1)            | 3                   |
| Paresthesia oral                                                   | 1 (<0.1)            | 1                   | 1 (<0.1)            | 1                   |
| Abdominal pain upper                                               | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Bowel movement irregularity                                         | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Gastroesophageal reflux disease                                    | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Lip swelling                                                       | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Parotid gland enlargement                                          | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Vomiting                                                           | 1 (<0.1)            | 1                   | 0                   | 0                   |
| **General disorders and administration site conditions**           |                     |                     |                     |                     |
| Pain                                                               | 6 (<0.1)            | 6                   | 0                   | 0                   |
| Fatigue                                                            | 3 (<0.1)            | 3                   | 1 (<0.1)            | 1                   |
| Influenza-like illness                                             | 2 (<0.1)            | 2                   | 0                   | 0                   |
| Asthenia                                                           | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Chest pain                                                         | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Chills                                                             | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Discomfort                                                         | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Feeling hot                                                        | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injection site erythema                                            | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injection site pain                                                | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injection site paresthesia                                         | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injection site pruritus                                            | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injection site reaction                                            | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Injury associated with device                                      | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Non-cardiac chest pain                                             | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Peripheral swelling                                                | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Reactogenicity event                                               | 0                   | 0                   | 1 (<0.1)            | 1                   |
| Swelling                                                           | 1 (<0.1)            | 1                   | 0                   | 0                   |
| **Immune system disorders**                                         |                     |                     |                     |                     |
| Drug hypersensitivity                                              | 1 (<0.1)            | 1                   | 0                   | 0                   |
| Category                                      | Count | Rate | Incidence | Severity |
|----------------------------------------------|-------|------|-----------|----------|
| Hypersensitivity                             | 1 (<0.1) | 1 | 0 | 0 |
| Infections and infestations                  | 6 (<0.1) | 6 | 1 (<0.1) | 1 |
| Herpes zoster                                | 4 (<0.1) | 4 | 0 | 0 |
| Cellulitis                                   | 1 (<0.1) | 1 | 0 | 0 |
| Injection site cellulitis                    | 1 (<0.1) | 1 | 0 | 0 |
| Nasopharyngitis                              | 0 | 0 | 1 (<0.1) | 1 |
| Injury, poisoning, and procedural complications| 3 (<0.1) | 3 | 2 (<0.1) | 2 |
| Injection-related reaction                   | 0 | 0 | 2 (<0.1) | 2 |
| Chilblains                                   | 1 (<0.1) | 1 | 0 | 0 |
| Seroma                                       | 1 (<0.1) | 1 | 0 | 0 |
| Skin laceration                              | 1 (<0.1) | 1 | 0 | 0 |
| Investigations                               | 3 (<0.1) | 3 | 0 | 0 |
| Body temperature increased                   | 3 (<0.1) | 3 | 0 | 0 |
| Metabolism and nutrition disorders           | 3 (<0.1) | 4 | 0 | 0 |
| Dehydration                                  | 1 (<0.1) | 1 | 0 | 0 |
| Hyperlactacidemia                            | 1 (<0.1) | 1 | 0 | 0 |
| Hypokalemia                                  | 1 (<0.1) | 1 | 0 | 0 |
| Vitamin B12 deficiency                       | 1 (<0.1) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | 9 (<0.1) | 9 | 5 (<0.1) | 5 |
| Arthralgia                                   | 3 (<0.1) | 3 | 0 | 0 |
| Back pain                                    | 0 | 0 | 2 (<0.1) | 2 |
| Muscle fatigue                               | 0 | 0 | 1 (<0.1) | 1 |
| Muscle spasms                                | 1 (<0.1) | 1 | 0 | 0 |
| Muscular weakness                            | 1 (<0.1) | 1 | 0 | 0 |
| Musculoskeletal pain                         | 1 (<0.1) | 1 | 0 | 0 |
| Myalgia                                      | 0 | 0 | 1 (<0.1) | 1 |
| Neck pain                                    | 1 (<0.1) | 1 | 0 | 0 |
| Pain in jaw                                  | 0 | 0 | 1 (<0.1) | 1 |
| Polymyalgia rheumatica                       | 1 (<0.1) | 1 | 0 | 0 |
| Rheumatoid arthritis                         | 1 (<0.1) | 1 | 0 | 0 |
| Nervous system disorders                     | 23 (0.1) | 29 | 3 (<0.1) | 8 |
| Paresthesia                                  | 8 (<0.1) | 8 | 2 (<0.1) | 5 |
| Hypoesthesia                                 | 4 (<0.1) | 4 | 1 (<0.1) | 2 |
| Dizziness                                    | 3 (<0.1) | 4 | 1 (<0.1) | 1 |
| Headache                                     | 4 (<0.1) | 4 | 0 | 0 |
| Syncope                                      | 2 (<0.1) | 2 | 0 | 0 |
| Ageusia                                      | 1 (<0.1) | 1 | 0 | 0 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | 1 (<0.1) | 1 | 0 | 0 |
| Facial paralysis                              | 1 (<0.1) | 1 | 0 | 0 |
| Guillain-Barré syndrome                      | 1 (<0.1) | 1 | 0 | 0 |
| Migraine                                     | 1 (<0.1) | 1 | 0 | 0 |
| Occipital neuralgia                           | 1 (<0.1) | 1 | 0 | 0 |
| Tremor                                       | 1 (<0.1) | 1 | 0 | 0 |
| Psychiatric disorders                        | 2 (<0.1) | 3 | 0 | 0 |
| Anxiety                                      | 1 (<0.1) | 1 | 0 | 0 |
| Depression                                   | 1 (<0.1) | 1 | 0 | 0 |
| Insomnia                                     | 1 (<0.1) | 1 | 0 | 0 |
| Respiratory, thoracic, and mediastinal disorders | 8 (<0.1) | 9 | 4 (<0.1) | 6 |
|-----------------------------------------------|---------|---|---------|---|
| Nasal congestion                              | 3 (<0.1) | 3 | 1 (<0.1) | 1 |
| Cough                                         | 2 (<0.1) | 2 | 1 (<0.1) | 1 |
| Dyspnea                                       | 2 (<0.1) | 2 | 1 (<0.1) | 1 |
| Oropharyngeal pain                            | 1 (<0.1) | 1 | 2 (<0.1) | 2 |
| Sinus congestion                              | 1 (<0.1) | 1 | 0       | 0 |
| Sneezing                                      | 0       | 0 | 1 (<0.1) | 1 |
| **Skin and subcutaneous tissue disorders**     | 6 (<0.1) | 7 | 5 (<0.1) | 5 |
| Dermatitis allergic                           | 1 (<0.1) | 1 | 1 (<0.1) | 1 |
| Rash maculo-papular                           | 1 (<0.1) | 1 | 1 (<0.1) | 1 |
| Urticaria                                     | 2 (<0.1) | 2 | 0       | 0 |
| Dermatitis                                    | 0       | 0 | 1 (<0.1) | 1 |
| Neurodermatitis                               | 0       | 0 | 1 (<0.1) | 1 |
| Petechiae                                     | 0       | 0 | 1 (<0.1) | 1 |
| Pruritus                                      | 1 (<0.1) | 2 | 0       | 0 |
| Seborrheic dermatitis                         | 1 (<0.1) | 1 | 0       | 0 |
| **Vascular disorders**                        | 2 (<0.1) | 2 | 0       | 0 |
| Hypertension                                  | 2 (<0.1) | 2 | 0       | 0 |

MAAEs are AEs leading to medically-attended visits that were not routine visits for physical examination, vaccination, or illness visit, such as an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. AEs, including abnormal vital signs, identified on a routine trial visit or during the scheduled illness visits were not be considered. MAAEs are reported through trial completion or withdrawal. AE, adverse event; MAAE, medically attended adverse event.
Table S5. Related Unsolicited AESIs by Category and Preferred Term for the Safety Analysis Set

| Category | AZD1222 (N=21,587) | Placebo (N=10,792) |
|----------|---------------------|---------------------|
|          | No. patients (%)    | No. events          | No. patients (%)    | No. events          |
| **Participants with 1 or more related AESI** | 58 (0.3) | 68 | 26 (0.2) | 34 |
| **Participants with any neurologic and/or neuroinflammatory related AESI** | 56 (0.3) | 66 | 26 (0.2) | 34 |
| **Neurologic** | | | | |
| Paresthesia | 34 (0.2) | 37 | 16 (0.1) | 22 |
| Hypoesthesia | 14 (<0.1) | 15 | 4 (<0.1) | 5 |
| Muscular weakness | 7 (<0.1) | 7 | 1 (<0.1) | 1 |
| Dysesthesia | 0 | 0 | 3 (<0.1) | 3 |
| Hyperesthesia | 3 (<0.1) | 3 | 0 | 0 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | 1 (<0.1) | 1 | 0 | 0 |
| Guillain-Barré syndrome | 1 (<0.1) | 1 | 0 | 0 |
| Neuritis | 0 | 0 | 1 (<0.1) | 1 |
| Neuropathy peripheral | 1 (<0.1) | 1 | 0 | 0 |
| Polyneuropathy | 0 | 0 | 1 (<0.1) | 1 |
| Sensory disturbance | 0 | 0 | 1 (<0.1) | 1 |
| **Potential Immune-Mediated Conditions** | 4 (<0.1) | 5 | 1 (<0.1) | 1 |
| Musculoskeletal disorders | 2 (<0.1) | 2 | 0 | 0 |
| Polymyalgia rheumatica | 1 (<0.1) | 1 | 0 | 0 |
| Rheumatoid arthritis | 1 (<0.1) | 1 | 0 | 0 |
| Neuroinflammatory disorders* | 2 (<0.1) | 3 | 1 (<0.1) | 1 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | 1 (<0.1) | 1 | 0 | 0 |
| Facial paralysis | 1 (<0.1) | 1 | 0 | 0 |
| Guillain-Barré syndrome | 1 (<0.1) | 1 | 0 | 0 |
| Polyneuropathy | 0 | 0 | 1 (<0.1) | 1 |

*The preferred terms in this category are included in the neurologic and potential immune-mediated conditions category of neuroinflammatory events. AESI, adverse event of special interest.
Table S6. Summary of SARS-CoV-2 Variants by Lineage, Based on Whole Genome NGS of Saliva Samples for the Full Analysis Set, Seronegative at Baseline

|                                | AZD1222 (N=20,589) | Placebo (N=10,300) | Total (N=30,889) |
|--------------------------------|---------------------|---------------------|------------------|
|                                | No. (%) | IR*    | No. (%) | IR    | No. (%) | IR    |
| **Total adjudicated cases**    |          |        |          |        |          |        |
| No lineage result\(^1\)        | 287 (1.39)| 64.98  | 303 (2.94)| 142.69| 590 (1.91)| 90.21 |
| Not sequenced\(^2\)            | 51 (0.25)| 11.55  | 49 (0.48)| 23.08 | 100 (0.32)| 15.29 |
| **Total variants sequenced**   | 125 (0.61)| 28.30  | 134 (1.30)| 63.10 | 259 (0.84)| 39.60 |
| **Variants of concern\(^3\)**  |          |        |          |        |          |        |
| Delta (B.1.617.2)               | 0       | 0      | 0       | 0      | 0       | 0      |
| Gamma (B.1.1.28.1/P.1)          | 0       | 0      | 0       | 0      | 0       | 0      |
| Alpha (B.1.1.7)                 | 1 (<0.01)| 0.23  | 1 (0.01)| 0.47  | 2 (0.01)| 0.31  |
| Beta (B.1.351)                  | 1 (<0.01)| 0.23  | 0       | 0      | 1 (<0.01)| 0.15  |
| **Variants of interest\(^4\)** |          |        |          |        |          |        |
| Zeta (B.1.1.28.2/P.2)           | 0       | 0      | 0       | 0      | 0       | 0      |
| Epsilon (B.1.427)               | 1 (<0.01)| 0.23  | 2 (0.02)| 0.94  | 3 (0.01)| 0.46  |
| Epsilon (B.1.429)               | 7 (0.03)| 1.58  | 7 (0.07)| 3.30  | 14 (0.05)| 2.14  |
| Eta (B.1.525)                   | 0       | 0      | 0       | 0      | 0       | 0      |
| Iota (B.1.526)                  | 1 (<0.01)| 0.23  | 0       | 0      | 1 (<0.01)| 0.15  |
| **Others**                      |          |        |          |        |          |        |
| A                               | 0       | 0      | 2 (0.02)| 0.94  | 2 (0.01)| 0.31  |
| B                               | 1 (<0.01)| 0.23  | 1 (0.01)| 0.47  | 2 (0.01)| 0.31  |
| B.1                             | 14 (0.07)| 3.17  | 17 (0.17)| 8.01  | 31 (0.10)| 4.74  |
| B.1.1.1                         | 0       | 0      | 1 (0.01)| 0.47  | 1 (<0.01)| 0.15  |
| B.1.1.220                       | 1 (<0.01)| 0.23  | 1 (0.01)| 0.47  | 2 (0.01)| 0.31  |
| B.1.1.222                       | 1 (<0.01)| 0.23  | 5 (0.05)| 2.35  | 6 (0.02)| 0.92  |
| Strain     | R0 | R1 | R2 | R4 | R6 | R8 | R10 |
|------------|----|----|----|----|----|----|-----|
| B.1.1.231  | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.1.29   | 0  | 0  | 2 (0.02) | 0.94 | 2 (0.01) | 0.31 |
| B.1.1.291  | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.1.296  | 1 (<0.01) | 0.23 | 1 (0.01) | 0.47 | 2 (0.01) | 0.31 |
| B.1.1.304  | 2 (0.01) | 0.45 | 2 (0.02) | 0.94 | 4 (0.01) | 0.61 |
| B.1.1.85   | 0  | 0  | 2 (0.02) | 0.94 | 2 (0.01) | 0.31 |
| B.1.110.3  | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.111    | 1 (<0.01) | 0.23 | 0 | 0 | 1 (<0.01) | 0.15 |
| B.1.139    | 2 (0.01) | 0.45 | 1 (0.01) | 0.47 | 3 (0.01) | 0.46 |
| B.1.181    | 1 (<0.01) | 0.23 | 0 | 0 | 1 (<0.01) | 0.15 |
| B.1.2      | 70 (0.34) | 15.85 | 64 (0.62) | 30.14 | 134 (0.43) | 20.49 |
| B.1.216    | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.234    | 4 (0.02) | 0.91 | 7 (0.07) | 3.30 | 11 (0.04) | 1.68 |
| B.1.239    | 2 (0.01) | 0.45 | 0 | 0 | 2 (0.01) | 0.31 |
| B.1.240    | 1 (<0.01) | 0.23 | 2 (0.02) | 0.94 | 3 (0.01) | 0.46 |
| B.1.241    | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.243    | 5 (0.02) | 1.13 | 4 (0.04) | 1.88 | 9 (0.03) | 1.38 |
| B.1.260    | 1 (<0.01) | 0.23 | 0 | 0 | 1 (<0.01) | 0.15 |
| B.1.311    | 1 (<0.01) | 0.23 | 2 (0.02) | 0.94 | 3 (0.01) | 0.46 |
| B.1.349    | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |
| B.1.361    | 3 (0.01) | 0.68 | 1 (0.01) | 0.47 | 4 (0.01) | 0.61 |
| B.1.369    | 2 (0.01) | 0.45 | 1 (0.01) | 0.47 | 3 (0.01) | 0.46 |
| B.1.404    | 1 (<0.01) | 0.23 | 1 (0.01) | 0.47 | 2 (0.01) | 0.31 |
| R.1        | 0  | 0  | 1 (0.01) | 0.47 | 1 (<0.01) | 0.15 |

*IR is provided as cases per 1000 person-years (number of cases/follow-up time in years).
†Insufficient sequence coverage for lineage designation.
‡Participants who were not sequenced for a saliva sample (specimen not available, or Ct greater than 30).
§Compiled based upon data from the WHO, MHRA. Described using WHO nomenclature (Pango lineage) where appropriate.
Ct, cycle threshold; IR, incidence rate; MHRA, Medicines and Healthcare products Regulatory Agency; NGS, next-generation sequencing; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
REFERENCES

1. Safety Platform for Emergency vACCines. D2.3 Priority list of adverse events of special interest: COVID-19. (Accessed June 25, 2021, at https://media.tghn.org/articles/COVID-19_AESIs_SPEAC_V1.1_5Mar2020.pdf.)

2. Guidance for Industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. (Accessed June 25, 2021, at https://www.fda.gov/media/73679/download.)

3. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.

4. CDC Symptoms of Coronavirus. 2021. (Accessed June 25, 2021, at https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.)

5. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.